Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioCryst Pharmaceuticals, Inc. (BCRX)
USD9.47
-0.27 (-2.81%)
US NASDAQ Healthcare Biotechnology
Address
4505 Emperor Boulevard 27703
Durham, NC, US
Durham, NC, US
CEO
Charles K. Gayer
Website
biocryst.com
IPO
1994-03-04
CIK 882796 ISIN US09058V1035
Description
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
News Sentiment (7d)
Based on only 1 article — low confidence
- BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.47
-0.27 (-2.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.57
Float Shares
182.26M
Free Float %
86.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46% | -2.50% | -10.25% | +26.18% | +19.50% | +10.00% | -17.02% | +3.37% | -31.31% | +202.11% | +32.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (29 ratings, all time)
Buy
Price Targets & DCF
Current price
9.47
Low
8.00
-15.5%
Consensus
16.86
+78.1%
Median
15.00
+58.5%
High
25.00
+164.1%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 5 |
14.40
+52.1%
|
| All Time | 12 |
15.42
+62.9%
|
Quality scores
Altman Z-Score
-5.98
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+94.1% ★ Q1'26: +7.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+381.4% ★
-
FCF margin FCF growth · Biotechnology: +16.2%+23.7% Q1'26: -40.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+39.6% ★ Q1'26: -448.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+409.6% ★ Q1'26: -4,318.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+5.8% Q1'26: +12.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.37× Q1'26: -0.31× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.64M
est: 15.65M (+25.5%)
|
26.29M
est: 52.76M (-50.2%)
|
17.33M
est: 19.07M (-9.1%)
|
13.61M
est: 17.21M (-20.9%)
|
48.26M
est: 49.15M (-1.8%)
|
26.35M
est: 22.56M (+16.8%)
|
25.19M
est: 26.50M (-5.0%)
|
20.65M
est: 20.75M (-0.5%)
|
48.84M
est: 18.97M (+157.5%)
|
17.81M
est: 28.56M (-37.6%)
|
157.17M
est: 160.40M (-2.0%)
|
270.83M
est: 265.41M (+2.0%)
|
331.41M
est: 382.24M (-13.3%)
|
450.71M
est: 449.34M (+0.3%)
|
874.84M
est: 619.55M (+41.2%)
|
671.03M
645.57M – 696.50M
+8.3% YoY
|
727.23M
686.46M – 767.98M
+8.4% YoY
|
863.96M
851.19M – 876.73M
+18.8% YoY
|
1.05B
998.47M – 1.12B
+22.0% YoY
|
1.25B
1.18B – 1.33B
+18.4% YoY
|
| EBITDA |
-52.29M
est: -38.18M (-36.9%)
|
-33.79M
est: -36.66M (+7.8%)
|
-25.03M
est: -22.65M (-10.5%)
|
-40.01M
est: -41.60M (+3.8%)
|
-37.64M
est: -33.31M (-13.0%)
|
-48.17M
est: -47.57M (-1.3%)
|
-56.51M
est: -49.27M (-14.7%)
|
-90.37M
est: -10.91M (-728.6%)
|
-96.28M
est: -9.97M (-865.6%)
|
-167.57M
est: -147.27M (-13.8%)
|
-121.74M
est: -95.83M (-27.0%)
|
-143.85M
est: -139.52M (-3.1%)
|
-116.34M
est: -94.10M (-23.6%)
|
12.81M
est: -110.62M (+111.6%)
|
347.65M
est: -152.53M (+327.9%)
|
-165.20M
-171.47M – -158.93M
-8.3% YoY
|
-179.04M
-189.07M – -169.00M
-8.4% YoY
|
-212.70M
-215.84M – -209.56M
-18.8% YoY
|
-259.52M
-275.90M – -245.81M
-22.0% YoY
|
-307.37M
-326.77M – -291.13M
-18.4% YoY
|
| EBIT |
-53.17M
est: -36.23M (-46.8%)
|
-34.42M
est: -36.62M (+6.0%)
|
-25.33M
est: -28.92M (+12.4%)
|
-40.19M
est: -49.95M (+19.5%)
|
-37.82M
est: -36.17M (-4.6%)
|
-48.66M
est: -51.56M (+5.6%)
|
-57.22M
est: -49.93M (-14.6%)
|
-92.08M
est: -10.98M (-738.5%)
|
-97.01M
est: -10.04M (-866.2%)
|
-168.31M
est: -155.72M (-8.1%)
|
-122.52M
est: -179.54M (+31.8%)
|
-145.29M
est: -140.47M (-3.4%)
|
-117.99M
est: -95.60M (-23.4%)
|
11.56M
est: -112.38M (+110.3%)
|
346.26M
est: -154.95M (+323.5%)
|
-167.83M
-174.20M – -161.46M
-8.3% YoY
|
-181.89M
-192.08M – -171.69M
-8.4% YoY
|
-216.08M
-219.28M – -212.89M
-18.8% YoY
|
-263.65M
-280.29M – -249.73M
-22.0% YoY
|
-312.27M
-331.97M – -295.77M
-18.4% YoY
|
| Net Income |
-56.95M
est: -41.75M (-36.4%)
|
-39.08M
est: -42.62M (+8.3%)
|
-30.11M
est: -27.69M (-8.7%)
|
-45.19M
est: -47.15M (+4.2%)
|
-43.02M
est: -40.32M (-6.7%)
|
-55.14M
est: -56.10M (+1.7%)
|
-65.78M
est: -57.50M (-14.4%)
|
-101.25M
est: -202.79M (+50.1%)
|
-108.90M
est: -251.94M (+56.8%)
|
-182.81M
est: -160.74M (-13.7%)
|
-184.06M
est: -161.72M (-13.8%)
|
-247.12M
est: -230.12M (-7.4%)
|
-226.54M
est: -159.83M (-41.7%)
|
-88.88M
est: -76.31M (-16.5%)
|
263.86M
est: 39.10M (+574.8%)
|
-670.15M
-771.18M – -404.87M
-1,813.8% YoY
|
60.77M
32.66M – 143.71M
+109.1% YoY
|
120.61M
37.52M – 191.18M
+98.5% YoY
|
199.64M
185.92M – 216.01M
+65.5% YoY
|
312.94M
291.44M – 338.61M
+56.8% YoY
|
| SGA |
12.33M
est: 8.43M (+46.3%)
|
6.83M
est: 7.78M (-12.2%)
|
5.22M
est: 5.20M (+0.3%)
|
7.46M
est: 8.00M (-6.7%)
|
13.05M
est: 17.39M (-25.0%)
|
11.25M
est: 12.92M (-12.9%)
|
13.93M
est: 12.07M (+15.4%)
|
29.51M
est: 26.53M (+11.2%)
|
37.12M
est: 24.26M (+53.0%)
|
67.93M
est: 36.52M (+86.0%)
|
118.82M
est: 123.25M (-3.6%)
|
159.37M
est: 339.40M (-53.0%)
|
213.89M
est: 227.72M (-6.1%)
|
266.13M
est: 267.70M (-0.6%)
|
348.65M
est: 369.11M (-5.5%)
|
399.78M
384.61M – 414.95M
+8.3% YoY
|
433.26M
408.97M – 457.54M
+8.4% YoY
|
514.72M
507.11M – 522.33M
+18.8% YoY
|
628.04M
594.86M – 667.66M
+22.0% YoY
|
743.83M
704.53M – 790.76M
+18.4% YoY
|
| EPS |
-1.26
est: -0.75 (-69.1%)
|
-0.79
est: -1.07 (+26.2%)
|
-0.55
est: -0.49 (-12.2%)
|
-0.68
est: -0.83 (+18.1%)
|
-0.59
est: -0.61 (+2.6%)
|
-0.75
est: -0.92 (+18.4%)
|
-0.78
est: -0.71 (-10.3%)
|
-0.98
est: -0.98 (+0.1%)
|
-0.94
est: -1.22 (+22.9%)
|
-1.09
est: -1.00 (-9.2%)
|
-1.03
est: -1.22 (+15.5%)
|
-1.33
est: -1.11 (-19.5%)
|
-1.18
est: -0.73 (-62.5%)
|
-0.43
est: -0.36 (-19.7%)
|
1.26
est: 0.14 (+796.4%)
|
-2.73
-3.53 – -1.85
-2,045.3% YoY
|
0.35
0.15 – 0.66
+112.7% YoY
|
0.43
0.17 – 0.87
+23.6% YoY
|
0.91
0.85 – 0.99
+113.2% YoY
|
1.43
1.33 – 1.55
+56.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 4/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
311.73M
OE per share TTM
1.44
Owner's Yield
14.57%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
60
Total invested
170.16M
Insider transactions (90d)
1
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Felix J. Baker | 18.46M | 9.95% | 18.46M | — | 18.46M | — | HC, IN | United States | 2022-02-14 | ↗ |
| 2 | Julian C. Baker | 18.46M | 9.95% | 18.46M | — | 18.46M | — | HC, IN | United States | 2022-02-14 | ↗ |
| 3 | Baker Bros. Advisors (GP) LLC | 18.39M | 9.91% | 18.39M | — | 18.39M | — | HC, OO | Delaware | 2022-02-14 | ↗ |
| 4 | Baker Bros. Advisors LP | 18.39M | 9.91% | 18.39M | — | 18.39M | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 5 | SSGA FUNDS MANAGEMENT, INC. | 14.82M | 8.39% | — | 14.77M | — | 14.82M | IA | BOSTON, MASSACHUSETTS | 2020-12-10 | ↗ |
| 6 | (1) BlackRock, Inc. | 14.79M | 8.20% | 14.26M | — | 14.79M | — | HC | Delaware | 2022-02-01 | ↗ |
| 7 | Avoro Capital Advisors LLC | 13.05M | 6.40% | 13.05M | — | 13.05M | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 8 | Behzad Aghazadeh | 13.05M | 6.40% | 13.05M | — | 13.05M | — | IN | United States | 2024-02-14 | ↗ |
| 9 | The Vanguard Group - 23-1945930 | 9.41M | 5.23% | — | 170.6K | 9.09M | 320.5K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 10 | Alexander J. Denner, Ph.D. | 8.84M | 5.00% | — | 8.84M | — | — | IN | Delaware | 2021-01-25 | ↗ |
| 11 | Sarissa Capital Management LP | 8.84M | 5.00% | 8.84M | — | 8.84M | — | PN | Delaware | 2021-01-25 | ↗ |
| 12 | STATE STREET CORPORATION | 8.25M | 4.58% | — | 7.88M | — | — | HC | — | 2022-02-09 | ↗ |
| 13 | Steven A. Cohen | 3.69M | 4.00% | — | 3.69M | — | 3.69M | IN | Delaware | 2021-02-16 | ↗ |
| 14 | Point72 Asset Management, L.P. | 3.23M | 4.00% | — | 3.23M | — | 3.23M | PN | Delaware | 2021-02-16 | ↗ |
| 15 | Point72 Capital Advisors, Inc. | 3.23M | 4.00% | — | 3.23M | — | 3.23M | CO | Delaware | 2021-02-16 | ↗ |
| 16 | Adage Capital Advisors, L.L.C. | 2.50M | 1.62% | — | 2.50M | — | — | OO | Delaware | 2020-04-17 | ↗ |
| 17 | Cubist Systematic Strategies, LLC | 456.6K | 4.00% | — | 456.6K | — | 456.6K | OO | Delaware | 2021-02-16 | ↗ |
| 18 | Israel A. Englander | 286.6K | 0.20% | — | 286.6K | — | 286.6K | IN | — | 2021-02-10 | ↗ |
| 19 | Millennium Group Management LLC | 286.6K | 0.20% | — | 286.6K | — | 286.6K | OO | — | 2021-02-10 | ↗ |
| 20 | Millennium Management LLC | 286.6K | 0.20% | — | 286.6K | — | 286.6K | OO | — | 2021-02-10 | ↗ |
| 21 | Millennium International Management LP | 255.5K | 0.10% | — | 255.5K | — | 255.5K | PN | — | 2021-02-10 | ↗ |
| 22 | ICS Opportunities II LLC | 151.0K | 0.10% | — | 151.0K | — | 151.0K | OO | — | 2021-02-10 | ↗ |
| 23 | Integrated Assets II LLC | 104.5K | 0.10% | — | 104.5K | — | 104.5K | OO | — | 2021-02-10 | ↗ |
| 24 | Integrated Core Strategies (US) LLC | 31.1K | 0.00% | — | 31.1K | — | 31.1K | OO | — | 2021-02-10 | ↗ |
| 25 | Kenneth Griffin | 10.00 | 3.80% | — | 6.66M | — | — | HC, IN | — | 2021-02-16 | ↗ |
| 26 | Citadel Advisors Holdings LP | 10.00 | 3.50% | — | 6.11M | — | — | HC, PN | — | 2021-02-16 | ↗ |
| 27 | Citadel Advisors LLC | 10.00 | 3.50% | — | 6.11M | — | — | IA, HC, OO | — | 2021-02-16 | ↗ |
| 28 | Citadel GP LLC | 10.00 | 3.50% | — | 6.11M | — | — | HC, OO | — | 2021-02-16 | ↗ |
| 29 | 2. | 10.00 | 0.30% | — | 547.3K | — | — | HC, OO | — | 2021-02-16 | ↗ |
| 30 | CALC IV LP | 10.00 | 0.30% | — | 547.3K | — | — | HC, PN | — | 2021-02-16 | ↗ |
| 31 | Citadel Securities LLC | 10.00 | 0.30% | — | 475.5K | — | — | BD, OO | — | 2021-02-16 | ↗ |
| 32 | Citadel Securities GP LLC | 10.00 | 0.20% | — | 371.8K | — | — | HC, OO | Delaware | 2020-06-10 | ↗ |
| 33 | Point72 Hong Kong Limited | — | 4.00% | — | 4.3K | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 34 | EIN #00-0000000 | — | 0.00% | — | — | — | — | IA, HC | Jersey Channel Islands | 2021-02-11 | ↗ |
| 35 | Integrated Assets, Ltd. | — | 0.00% | — | — | — | — | CO | — | 2021-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
60
-231 vs prev Q
New positions
11
Closed positions
227
Increased
31
Reduced
16
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 2.15M +2.2M (+100.0%) | 16.77B +16.8B (+100.0%) | 1.02% +1.023 pp | 4.95% +4.949 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 22.27M +482.5K (+2.2%) | 173.73M +8.3M (+5.0%) | 10.60% +0.181 pp | 0.00% +0.000 pp | USD8.00 -2.5% | 84 qtrs — |
| 3 | BLACKROCK, INC. | 21.14M -108.1K (-0.5%) | 164.87M +3.6M (+2.2%) | 10.06% -0.098 pp | 0.00% +0.000 pp | USD7.59 +2.8% | 6 qtrs — |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 15.83M +15.8M (+100.0%) | 123.45M +123.5M (+100.0%) | 7.53% +7.530 pp | 1.26% +1.265 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 14.34M +2.2M (+17.8%) | 111.86M +19.5M (+21.1%) | 6.82% +1.007 pp | 1.43% +0.019 pp | USD7.38 +5.7% | 12 qtrs — |
| 6 | STATE STREET CORP | 11.07M +1.3M (+12.9%) | 86.37M +11.9M (+16.0%) | 5.27% +0.581 pp | 0.00% +0.000 pp | USD7.49 +4.1% | 51 qtrs — |
| 7 | KYNAM CAPITAL MANAGEMENT, LP | 9.37M -23.7K (-0.3%) | 73.06M +1.8M (+2.5%) | 4.46% -0.032 pp | 4.67% -0.640 pp | USD6.62 +17.8% | 15 qtrs — |
| 8 | JANUS HENDERSON GROUP PLC | 7.40M +7.3M (+7,807.2%) | 57.79M +57.1M (+8,036.6%) | 3.52% +3.478 pp | 0.03% +0.026 pp | USD7.84 -0.5% | 18 qtrs — |
| 9 | UBS GROUP AG | 5.26M -703.8K (-11.8%) | 41.06M -4.2M (-9.4%) | 2.50% -0.348 pp | 0.01% 0.000 pp | USD8.28 -5.8% | 45 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 5.05M +1.5K (+0.0%) | 39.43M +1.1M (+2.8%) | 2.40% -0.011 pp | 0.00% +0.000 pp | USD7.14 +9.2% | 78 qtrs — |
| 11 | TWO SIGMA INVESTMENTS, LP | 4.52M +95.7K (+2.2%) | 35.22M +1.7M (+5.0%) | 2.15% +0.036 pp | 0.05% 0.000 pp | USD8.58 -9.1% | 37 qtrs — |
| 12 | TWO SIGMA ADVISERS, LP | 4.09M -151.6K (-3.6%) | 31.90M -291.9K (-0.9%) | 1.95% -0.082 pp | 0.06% -0.002 pp | USD9.66 -19.3% | 36 qtrs — |
| 13 | NUVEEN, LLC | 3.61M -5.5K (-0.2%) | 28.18M +716.7K (+2.6%) | 1.72% -0.011 pp | 0.01% +0.000 pp | USD8.35 -6.6% | 4 qtrs — |
| 14 | GOLDMAN SACHS GROUP INC | 3.21M +501.0K (+18.5%) | 25.06M +4.5M (+21.8%) | 1.53% +0.232 pp | 0.00% +0.001 pp | USD8.55 -8.8% | 67 qtrs — |
| 15 | PERCEPTIVE ADVISORS LLC | 3.16M +3.2M (+100.0%) | 24.67M +24.7M (+100.0%) | 1.50% +1.505 pp | 0.44% +0.440 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 16 | GW&K INVESTMENT MANAGEMENT, LLC | 3.16M +963.2K (+43.8%) | 24.66M +8.0M (+47.8%) | 1.50% +0.453 pp | 0.21% +0.066 pp | USD8.70 -10.3% | 14 qtrs — |
| 17 | EVERSEPT PARTNERS, LP | 2.99M +1.6M (+117.9%) | 23.34M +12.9M (+123.9%) | 1.42% +0.767 pp | 1.18% +0.458 pp | USD7.81 -0.1% | 13 qtrs — |
| 18 | BAKER BROS. ADVISORS LP | 2.82M +2.8M (+100.0%) | 22.02M +22.0M (+100.0%) | 1.34% +1.343 pp | 0.13% +0.129 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 19 | BNP PARIBAS ARBITRAGE, SNC | 2.54M +448.4K (+21.4%) | 19.83M +3.9M (+24.8%) | 1.21% +0.209 pp | 0.01% +0.001 pp | USD8.34 -6.5% | 46 qtrs — |
| 20 | FISHER ASSET MANAGEMENT, LLC | 2.47M -165.1K (-6.3%) | 19.25M -735.1K (-3.7%) | 1.17% -0.084 pp | 0.01% -0.001 pp | USD12.96 -39.8% | 19 qtrs — |
| 21 | VESTAL POINT CAPITAL, LP | 2.25M +2.3M (+100.0%) | 17.55M +17.6M (+100.0%) | 1.07% +1.071 pp | 0.60% +0.597 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 22 | QUBE RESEARCH & TECHNOLOGIES LTD | 2.16M -246.2K (-10.2%) | 16.88M -1.4M (-7.7%) | 1.03% -0.123 pp | 0.02% -0.002 pp | USD8.38 -6.9% | 11 qtrs — |
| 23 | RENAISSANCE TECHNOLOGIES LLC | 2.13M -11.7K (-0.5%) | 16.60M +358.2K (+2.2%) | 1.01% -0.010 pp | 0.03% +0.004 pp | USD8.31 -6.1% | 10 qtrs — |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.00M +10.5K (+0.5%) | 15.64M +501.0K (+3.3%) | 0.95% +0.001 pp | 0.00% +0.000 pp | USD6.99 +11.6% | 61 qtrs — |
| 25 | RICE HALL JAMES & ASSOCIATES, LLC | 1.90M +23.8K (+1.3%) | 14.85M +580.2K (+4.1%) | 0.91% +0.007 pp | 0.82% +0.039 pp | USD7.11 +9.7% | 11 qtrs — |
| 26 | NORTHERN TRUST CORP | 1.86M -35.1K (-1.9%) | 14.48M +123.2K (+0.9%) | 0.88% -0.021 pp | 0.00% +0.000 pp | USD8.26 -5.6% | 51 qtrs — |
| 27 | STIFEL FINANCIAL CORP | 1.82M +1.5K (+0.1%) | 14.23M +394.7K (+2.9%) | 0.87% -0.003 pp | 0.01% +0.000 pp | USD2.01 +288.1% | 24 qtrs — |
| 28 | MORGAN STANLEY | 1.75M -3.5M (-66.5%) | 13.62M -25.9M (-65.5%) | 0.83% -1.657 pp | 0.00% -0.002 pp | USD8.35 -6.6% | 51 qtrs — |
| 29 | ORBIMED ADVISORS LLC | 1.74M +840.3K (+93.2%) | 13.59M +6.7M (+98.6%) | 0.83% +0.398 pp | 0.28% +0.117 pp | USD7.69 +1.4% | 2 qtrs — |
| 30 | SQUAREPOINT OPS LLC | 1.66M +550.5K (+49.7%) | 12.94M +4.5M (+53.8%) | 0.79% +0.260 pp | 0.01% +0.005 pp | USD7.63 +2.2% | 17 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 1.54M -367.3K (-19.3%) | 11.98M -2.5M (-17.1%) | 0.73% -0.179 pp | 0.00% 0.000 pp | USD8.54 -8.7% | 52 qtrs — |
| 32 | NANTAHALA CAPITAL MANAGEMENT, LLC | 1.36M +1.4M (+100.0%) | 10.58M +10.6M (+100.0%) | 0.65% +0.645 pp | 0.35% +0.350 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 33 | INVESCO LTD. | 1.35M +392.5K (+40.8%) | 10.57M +3.3M (+44.7%) | 0.64% +0.185 pp | 0.00% +0.001 pp | USD7.88 -1.0% | 23 qtrs — |
| 34 | CITADEL ADVISORS LLC | 1.30M -61.0K (-4.5%) | 10.13M -190.1K (-1.8%) | 0.62% -0.032 pp | 0.00% +0.000 pp | USD8.62 -9.5% | 37 qtrs — |
| 35 | D. E. SHAW & CO., INC. | 1.25M -461.9K (-27.0%) | 9.73M -3.2M (-25.0%) | 0.59% -0.224 pp | 0.01% -0.002 pp | USD8.38 -6.9% | 21 qtrs — |
| 36 | DIMENSIONAL FUND ADVISORS LP | 1.23M +1.2M (+100.0%) | 9.59M +9.6M (+100.0%) | 0.58% +0.585 pp | 0.00% +0.002 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 37 | POINT72 ASSET MANAGEMENT, L.P. | 1.21M +975.4K (+409.5%) | 9.47M +7.7M (+423.6%) | 0.58% +0.464 pp | 0.01% +0.008 pp | USD7.76 +0.5% | 2 qtrs — |
| 38 | JUPITER ASSET MANAGEMENT LTD | 1.20M -858.3K (-41.7%) | 9.34M -6.3M (-40.1%) | 0.57% -0.413 pp | 0.07% -0.059 pp | USD7.55 +3.3% | 6 qtrs — |
| 39 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1.03M +661.0K (+178.4%) | 8.05M +5.2M (+186.1%) | 0.49% +0.314 pp | 0.03% +0.020 pp | USD7.74 +0.8% | 14 qtrs — |
| 40 | HUDSON BAY CAPITAL MANAGEMENT LP | 1.02M +1.0M (+100.0%) | 7.94M +7.9M (+100.0%) | 0.48% +0.484 pp | 0.03% +0.026 pp | USD7.80 +0.0% | 4 qtrs — |
| 41 | ABRDN PLC | 913.6K +913.6K (+100.0%) | 7.13M +7.1M (+100.0%) | 0.43% +0.435 pp | 0.01% +0.011 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 42 | JUMP FINANCIAL, LLC | 910.9K -13.8K (-1.5%) | 7.11M +86.2K (+1.2%) | 0.43% -0.009 pp | 0.09% +0.003 pp | USD8.73 -10.7% | 12 qtrs — |
| 43 | PARKMAN HEALTHCARE PARTNERS LLC | 900.1K -112.6K (-11.1%) | 7.02M -665.7K (-8.7%) | 0.43% -0.056 pp | 0.67% -0.133 pp | USD7.36 +6.0% | 7 qtrs — |
| 44 | JPMORGAN CHASE & CO | 843.4K -289.0K (-25.5%) | 6.58M -2.0M (-23.5%) | 0.40% -0.140 pp | 0.00% 0.000 pp | USD8.11 -3.8% | 37 qtrs — |
| 45 | SPHERA FUNDS MANAGEMENT LTD. | 837.9K +837.9K (+100.0%) | 6.54M +6.5M (+100.0%) | 0.40% +0.399 pp | 1.26% +1.263 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 46 | TANG CAPITAL MANAGEMENT LLC | 800.0K +— (+0.0%) | 6.24M +168.0K (+2.8%) | 0.38% -0.002 pp | 0.31% +0.075 pp | USD9.31 -16.2% | 15 qtrs — |
| 47 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 778.5K +778.5K (+100.0%) | 6.07M +6.1M (+100.0%) | 0.37% +0.370 pp | 0.09% +0.094 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 48 | PICTET ASSET MANAGEMENT HOLDING SA | 740.5K -455.8K (-38.1%) | 5.71M -3.3M (-36.8%) | 0.35% -0.220 pp | 0.01% -0.003 pp | USD7.95 -1.9% | 10 qtrs — |
| 49 | BARCLAYS PLC | 726.4K +249.7K (+52.4%) | 5.67M +2.0M (+56.4%) | 0.35% +0.118 pp | 0.00% +0.000 pp | USD8.47 -7.9% | 51 qtrs — |
| 50 | HRT FINANCIAL LP | 716.8K +658.9K (+1,137.9%) | 5.59M +5.2M (+1,173.6%) | 0.34% +0.313 pp | 0.02% +0.016 pp | USD7.84 -0.5% | 6 qtrs — |
| 51 | AQR CAPITAL MANAGEMENT LLC | 704.3K -295.5K (-29.6%) | 5.49M -2.1M (-27.6%) | 0.34% -0.143 pp | 0.00% -0.002 pp | USD6.97 +11.9% | 29 qtrs — |
| 52 | PDT PARTNERS, LLC | 683.4K +— (+0.0%) | 5.33M +143.5K (+2.8%) | 0.33% -0.002 pp | 0.35% +0.019 pp | USD7.58 +2.9% | 14 qtrs — |
| 53 | JANE STREET GROUP, LLC | 649.4K -1.2M (-64.9%) | 5.06M -9.0M (-63.9%) | 0.31% -0.575 pp | 0.00% -0.001 pp | USD7.55 +3.3% | 27 qtrs — |
| 54 | VOYA INVESTMENT MANAGEMENT LLC | 625.5K +169.9K (+37.3%) | 4.88M +1.4M (+41.1%) | 0.30% +0.080 pp | 0.00% +0.001 pp | USD8.38 -6.9% | 47 qtrs — |
| 55 | BANK OF NEW YORK MELLON CORP | 608.0K -12.0K (-1.9%) | 4.74M +36.6K (+0.8%) | 0.29% -0.007 pp | 0.00% 0.000 pp | USD8.05 -3.1% | 66 qtrs — |
| 56 | FRANKLIN RESOURCES INC | 570.2K +104.9K (+22.5%) | 4.45M +915.6K (+25.9%) | 0.27% +0.049 pp | 0.00% +0.000 pp | USD7.42 +5.1% | 8 qtrs — |
| 57 | FMR LLC | 560.2K -93.6K (-14.3%) | 4.37M -593.0K (-12.0%) | 0.27% -0.046 pp | 0.00% +0.000 pp | USD12.64 -38.3% | 50 qtrs — |
| 58 | HILLSDALE INVESTMENT MANAGEMENT INC. | 559.1K -2.5K (-0.4%) | 4.36M +98.4K (+2.3%) | 0.27% -0.002 pp | 0.12% -0.008 pp | USD7.56 +3.2% | 6 qtrs — |
| 59 | DEUTSCHE BANK AG\ | 491.1K -577.9K (-54.1%) | 3.83M -4.3M (-52.8%) | 0.23% -0.277 pp | 0.00% -0.002 pp | USD7.10 +9.9% | 50 qtrs — |
| 60 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 449.7K -507.3K (-53.0%) | 3.51M -3.8M (-51.7%) | 0.21% -0.244 pp | 0.01% -0.012 pp | USD7.20 +8.3% | 13 qtrs — |
| 61 | DAFNA CAPITAL MANAGEMENT LLC | 418.3K +200.0K (+91.6%) | 3.26M +1.6M (+96.9%) | 0.20% +0.095 pp | 0.76% +0.349 pp | USD8.47 -7.9% | 13 qtrs — |
| 62 | MAN GROUP PLC | 407.9K +53.4K (+15.1%) | 3.18M +490.7K (+18.2%) | 0.19% +0.025 pp | 0.01% +0.001 pp | USD8.12 -3.9% | 6 qtrs — |
| 63 | SWISS NATIONAL BANK | 394.4K +9.0K (+2.3%) | 3.08M +151.1K (+5.2%) | 0.19% +0.003 pp | 0.00% +0.000 pp | USD6.55 +19.1% | 49 qtrs — |
| 64 | RAFFERTY ASSET MANAGEMENT, LLC | 382.6K +13.2K (+3.6%) | 2.98M +180.8K (+6.4%) | 0.18% +0.006 pp | 0.01% +0.001 pp | USD8.07 -3.3% | 28 qtrs — |
| 65 | UBS ASSET MANAGEMENT AMERICAS INC | 378.9K -15.9K (-4.0%) | 2.96M -41.0K (-1.4%) | 0.18% -0.008 pp | 0.00% +0.000 pp | USD7.80 +0.0% | 49 qtrs — |
| 66 | PRINCIPAL FINANCIAL GROUP INC | 376.6K +132.2K (+54.1%) | 2.94M +1.1M (+58.3%) | 0.18% +0.062 pp | 0.00% +0.001 pp | USD8.30 -6.0% | 47 qtrs — |
| 67 | FIRST TRUST ADVISORS LP | 375.0K -360.0K (-49.0%) | 2.92M -2.7M (-47.6%) | 0.18% -0.173 pp | 0.00% -0.002 pp | USD8.05 -3.1% | 19 qtrs — |
| 68 | ASSENAGON ASSET MANAGEMENT S.A. | 359.6K -2.7M (-88.4%) | 2.80M -20.7M (-88.1%) | 0.17% -1.307 pp | 0.00% -0.028 pp | USD8.96 -12.9% | 20 qtrs — |
| 69 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 357.1K -491.5K (-57.9%) | 2.79M -3.7M (-56.8%) | 0.17% -0.236 pp | 0.01% -0.013 pp | USD7.72 +1.0% | 13 qtrs — |
| 70 | STATE OF WISCONSIN INVESTMENT BOARD | 347.2K -28.7K (-7.6%) | 2.71M -144.6K (-5.1%) | 0.17% -0.015 pp | 0.01% -0.001 pp | USD6.97 +11.9% | 35 qtrs — |
| 71 | LOS ANGELES CAPITAL MANAGEMENT LLC | 355.1K +45.9K (+14.9%) | 2.57M +228.0K (+9.7%) | 0.17% +0.021 pp | 0.01% +0.001 pp | USD7.25 +7.6% | 11 qtrs — |
| 72 | CANADA PENSION PLAN INVESTMENT BOARD | 327.9K +97.6K (+42.4%) | 2.56M +809.7K (+46.3%) | 0.16% +0.046 pp | 0.00% +0.001 pp | USD8.65 -9.8% | 14 qtrs — |
| 73 | VICTORY CAPITAL MANAGEMENT INC | 325.1K +265.6K (+446.4%) | 2.54M +2.1M (+461.5%) | 0.15% +0.126 pp | 0.00% +0.001 pp | USD8.22 -5.1% | 26 qtrs — |
| 74 | FEDERATED HERMES, INC. | 292.9K +27.3K (+10.3%) | 2.28M +269.0K (+13.4%) | 0.14% +0.012 pp | 0.00% +0.000 pp | USD8.07 -3.3% | 6 qtrs — |
| 75 | ALLIANCEBERNSTEIN L.P. | 278.2K -143.0 (-0.1%) | 2.17M +57.3K (+2.7%) | 0.13% -0.001 pp | 0.00% +0.000 pp | USD7.28 +7.1% | 47 qtrs — |
| 76 | DOLIVER ADVISORS, LP | 274.3K +— (+0.0%) | 2.14M +57.6K (+2.8%) | 0.13% -0.001 pp | 0.54% -0.003 pp | USD10.43 -25.2% | 18 qtrs — |
| 77 | RHUMBLINE ADVISERS | 266.6K -60.3K (-18.4%) | 2.08M -401.5K (-16.2%) | 0.13% -0.029 pp | 0.00% 0.000 pp | USD8.29 -5.9% | 47 qtrs — |
| 78 | HUSSMAN STRATEGIC ADVISORS, INC. | 252.0K +42.0K (+20.0%) | 1.97M +371.7K (+23.3%) | 0.12% +0.020 pp | 0.48% +0.130 pp | USD7.55 +3.3% | 4 qtrs — |
| 79 | WALLEYE CAPITAL LLC | 251.7K +24.6K (+10.8%) | 1.96M +239.6K (+13.9%) | 0.12% +0.011 pp | 0.01% 0.000 pp | USD8.73 -10.7% | 19 qtrs — |
| 80 | PHOCAS FINANCIAL CORP. | 250.8K +250.8K (+100.0%) | 1.96M +2.0M (+100.0%) | 0.12% +0.119 pp | 0.25% +0.254 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 81 | BRIDGEWATER ASSOCIATES, LP | 235.6K -175.9K (-42.8%) | 1.84M -1.3M (-41.2%) | 0.11% -0.085 pp | 0.01% -0.006 pp | USD7.59 +2.8% | 2 qtrs — |
| 82 | WELLS FARGO & COMPANY/MN | 233.6K +100.6K (+75.6%) | 1.82M +812.6K (+80.5%) | 0.11% +0.048 pp | 0.00% +0.000 pp | USD7.82 -0.3% | 57 qtrs — |
| 83 | VIRGINIA RETIREMENT SYSTEMS ET AL | 233.4K +120.4K (+106.5%) | 1.82M +962.5K (+112.2%) | 0.11% +0.057 pp | 0.01% +0.005 pp | USD7.83 -0.4% | 4 qtrs — |
| 84 | RUSSELL INVESTMENTS GROUP, LTD. | 229.2K -85.3K (-27.1%) | 1.79M -599.0K (-25.1%) | 0.11% -0.041 pp | 0.00% -0.001 pp | USD8.60 -9.3% | 18 qtrs — |
| 85 | ENGINEERS GATE MANAGER LP | 224.5K -218.3K (-49.3%) | 1.75M -1.6M (-47.9%) | 0.11% -0.105 pp | 0.02% -0.018 pp | USD7.66 +1.8% | 14 qtrs — |
| 86 | GOTHAM ASSET MANAGEMENT, LLC | 216.9K -126.8K (-36.9%) | 1.69M -917.0K (-35.1%) | 0.10% -0.061 pp | 0.01% -0.005 pp | USD8.21 -5.0% | 6 qtrs — |
| 87 | LEGAL & GENERAL GROUP PLC | 211.0K -15.2K (-6.7%) | 1.65M -70.8K (-4.1%) | 0.10% -0.008 pp | 0.00% +0.000 pp | USD8.16 -4.4% | 46 qtrs — |
| 88 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 200.3K +131.6K (+191.6%) | 1.56M +1.0M (+199.6%) | 0.10% +0.063 pp | 0.00% +0.000 pp | USD7.71 +1.2% | 51 qtrs — |
| 89 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 200.0K +200.0K (+100.0%) | 1.56M +1.6M (+100.0%) | 0.10% +0.095 pp | 0.08% +0.078 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 90 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 191.8K +9.4K (+5.1%) | 1.50M +111.5K (+8.1%) | 0.09% +0.004 pp | 0.00% +0.000 pp | USD7.75 +0.6% | 47 qtrs — |
| 91 | DIADEMA PARTNERS LP | 190.9K +190.9K (+100.0%) | 1.49M +1.5M (+100.0%) | 0.09% +0.091 pp | 0.26% +0.257 pp | USD7.80 +0.0% | 1 qtrs NEW |
| 92 | PRICE T ROWE ASSOCIATES INC /MD/ | 177.4K +16.0K (+9.9%) | 1.38M +159.0K (+13.0%) | 0.08% +0.007 pp | 0.00% +0.000 pp | USD7.13 +9.4% | 25 qtrs — |
| 93 | ROYAL BANK OF CANADA | 161.5K -24.0K (-12.9%) | 1.26M -146.0K (-10.4%) | 0.08% -0.012 pp | 0.00% +0.000 pp | USD8.66 -9.9% | 37 qtrs — |
| 94 | MACKENZIE FINANCIAL CORP | 150.7K +21.4K (+16.6%) | 1.15M +170.8K (+17.4%) | 0.07% +0.010 pp | 0.00% +0.000 pp | USD7.56 +3.2% | 18 qtrs — |
| 95 | QTR FAMILY WEALTH, LLC | 154.1K -3.1K (-2.0%) | 1.01M -183.6K (-15.4%) | 0.07% -0.002 pp | 0.44% -0.122 pp | USD7.51 +3.9% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 113 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Biotechnology & Genome ETF PBE | 3.01% | 8.60M | 0.58% |
| 2 | Virtus Biotech ETF BBP | 1.55% | 1.52M | 0.34% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 1.36% | 2.89M | 0.50% |
| 4 | Janus Henderson Small/Mid Cap Growth Alpha ETF JSMD | 1.02% | 11.00M | 0.30% |
| 5 | Xtrackers LPX Private Equity Swap UCITS ETF 1C XLPE.L | 1.00% | 3.17M | 0.70% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.93% | 333.3K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 0.93% | 100.40M | 0.35% |
| 8 | Janus Henderson Small Cap Growth Alpha ETF JSML | 0.69% | 2.55M | 0.30% |
| 9 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.30% | 3.39M | 0.40% |
| 10 | Barron's 400SM ETF BFOR | 0.28% | 637.5K | 0.65% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
646.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+646,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-17 | Dullinger Ronald | Officer | — | — | Emp. Stock Option (Right to Buy) | 255,050 | 7.13 | 1.82M | 0 | D | ↗ |
| 2026-04-06 | Menon Sandeep | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-20 | HEGGIE THERESA | Director | M-Exempt | A | Common Stock | 49,933 | 6.30 | 314.6K | 115,285 | D | ↗ |
| 2026-03-16 | Barnes Alane P | Officer | M-Exempt | A | Common Stock | 150,000 | 5.51 | 826.5K | 550,703 | D | ↗ |
| 2026-03-02 | Stonehouse Jon P | Director | M-Exempt | A | Common Stock | 305,995 | 3.22 | 985.3K | 1,629,845 | D | ↗ |
| 2026-02-27 | Stonehouse Jon P | Director | A-Award | A | Common Stock | 421 | 8.75 | 3.7K | 1,323,850 | D | ↗ |
| 2026-02-27 | Milne Jill C. | Director | A-Award | A | Common Stock | 528 | 8.75 | 4.6K | 15,382 | D | ↗ |
| 2026-02-27 | McKee Amy E | Director | A-Award | A | Common Stock | 642 | 8.75 | 5.6K | 42,432 | D | ↗ |
| 2026-02-27 | MILANO VINCENT | Director | A-Award | A | Common Stock | 848 | 8.75 | 7.4K | 92,067 | D | ↗ |
| 2026-02-27 | Frank Steven | Director | A-Award | A | Common Stock | 1,285 | 8.75 | 11.2K | 18,903 | D | ↗ |
| 2026-01-23 | Milne Jill C. | Director | A-Award | A | Common Stock | 2,582 | 8.55 | 22.1K | 2,582 | D | ↗ |
| 2026-01-01 | Dullinger Ronald | Officer | — | — | Common Stock | 0 | 0.00 | — | 258,372 | D | ↗ |
| 2025-12-22 | Gayer Charles K | Officer | M-Exempt | D | Emp. Stock Option (Right to Buy) | 50,000 | 5.51 | 275.5K | 0 | D | ↗ |
| 2025-12-22 | Barnes Alane P | Officer | S-Sale | D | Common Stock | 21,773 | 7.65 | 166.6K | 398,751 | D | ↗ |
| 2025-12-19 | Stonehouse Jon P | Director / Officer | F-InKind | D | Common Stock | 61,793 | 7.41 | 457.9K | 1,323,429 | D | ↗ |
| 2025-12-19 | Gayer Charles K | Officer | F-InKind | D | Common Stock | 11,477 | 7.41 | 85.0K | 878,350 | D | ↗ |
| 2025-12-19 | Dullinger Ronald | Officer | — | — | Emp. Stock Option (Right to Buy) | 68,500 | 7.39 | 506.2K | 0 | D | ↗ |
| 2025-12-19 | Barnes Alane P | Officer | F-InKind | D | Common Stock | 16,902 | 7.41 | 125.2K | 420,524 | D | ↗ |
| 2025-12-18 | Stonehouse Jon P | Director / Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 1,385,222 | D | ↗ |
| 2025-12-17 | Ghias Babar | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 355,050 | 7.13 | 2.53M | 355,050 | D | ↗ |
| 2025-12-17 | Gayer Charles K | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 986,950 | 7.13 | 7.04M | 986,950 | D | ↗ |
| 2025-12-17 | Barnes Alane P | Officer | A-Award | A | Common Stock | 121,700 | 0.00 | — | 437,426 | D | ↗ |
| 2025-12-15 | Barnes Alane P | Officer | S-Sale | D | Common Stock | 21,210 | 7.65 | 162.3K | 315,726 | D | ↗ |
| 2025-12-12 | Stonehouse Jon P | Director / Officer | F-InKind | D | Common Stock | 27,368 | 7.57 | 207.2K | 1,405,222 | D | ↗ |
| 2025-12-12 | Gayer Charles K | Officer | F-InKind | D | Common Stock | 8,181 | 7.57 | 61.9K | 418,827 | D | ↗ |
| 2025-12-12 | Barnes Alane P | Officer | F-InKind | D | Common Stock | 8,540 | 7.57 | 64.6K | 336,936 | D | ↗ |
| 2025-12-03 | Barnes Alane P | Officer | S-Sale | D | Common Stock | 19,770 | 7.65 | 151.2K | 345,476 | D | ↗ |
| 2025-12-02 | Barnes Alane P | Officer | S-Sale | D | Common Stock | 50,906 | 7.21 | 367.2K | 365,246 | D | ↗ |
| 2025-12-01 | Barnes Alane P | Officer | M-Exempt | A | Common Stock | 91,004 | 3.22 | 293.0K | 507,156 | D | ↗ |
| 2025-11-28 | McKee Amy E | Director | A-Award | A | Common Stock | 783 | 7.18 | 5.6K | 41,790 | D | ↗ |
| 2025-11-28 | MILANO VINCENT | Director | A-Award | A | Common Stock | 783 | 7.18 | 5.6K | 91,219 | D | ↗ |
| 2025-11-28 | Frank Steven | Director | A-Award | A | Common Stock | 1,566 | 7.18 | 11.2K | 17,618 | D | ↗ |
| 2025-11-13 | SANDERS MACHELLE | Director | S-Sale | D | Common Stock | 9,600 | 7.14 | 68.5K | 30,642 | D | ↗ |
| 2025-08-29 | McKee Amy E | Director | A-Award | A | Common Stock | 676 | 8.31 | 5.6K | 41,007 | D | ↗ |
| 2025-08-29 | MILANO VINCENT | Director | A-Award | A | Common Stock | 676 | 8.31 | 5.6K | 90,436 | D | ↗ |
| 2025-08-29 | Frank Steven | Director | A-Award | A | Common Stock | 1,353 | 8.31 | 11.2K | 16,052 | D | ↗ |
| 2025-08-13 | HEGGIE THERESA | Director | M-Exempt | A | Common Stock | 40,000 | 5.41 | 216.4K | 135,352 | D | ↗ |
| 2025-07-24 | Ghias Babar | Officer | A-Award | A | Common Stock | 147,000 | 0.00 | — | 147,000 | D | ↗ |
| 2025-07-07 | Ghias Babar | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-12 | SANDERS MACHELLE | Director | A-Award | A | Automatic Stock Option Grant | 27,181 | 10.40 | 282.7K | 27,181 | D | ↗ |
| 2025-06-12 | McKee Amy E | Director | A-Award | A | Common Stock | 12,500 | 0.00 | — | 40,331 | D | ↗ |
| 2025-06-12 | MILANO VINCENT | Director | A-Award | A | Automatic Stock Option Grant | 27,181 | 10.40 | 282.7K | 27,181 | D | ↗ |
| 2025-06-12 | LEVIN ALAN G | Director | A-Award | A | Automatic Stock Option Grant | 27,181 | 10.40 | 282.7K | 27,181 | D | ↗ |
| 2025-06-12 | Hutson Nancy J | Director | A-Award | A | Common Stock | 12,500 | 0.00 | — | 99,138 | D | ↗ |
| 2025-06-12 | HEGGIE THERESA | Director | A-Award | A | Automatic Stock Option Grant | 27,181 | 10.40 | 282.7K | 27,181 | D | ↗ |
| 2025-06-12 | Galson Steven K | Director | A-Award | A | Common Stock | 12,500 | 0.00 | — | 24,991 | D | ↗ |
| 2025-06-12 | Frank Steven | Director | A-Award | A | Automatic Stock Option Grant | 27,181 | 10.40 | 282.7K | 27,181 | D | ↗ |
| 2025-05-30 | MILANO VINCENT | Director | A-Award | A | Common Stock | 523 | 10.75 | 5.6K | 77,260 | D | ↗ |
| 2025-05-30 | Frank Steven | Director | A-Award | A | Common Stock | 333 | 10.75 | 3.6K | 2,199 | D | ↗ |
| 2025-05-02 | Frank Steven | Director | A-Award | A | Automatic Stock Option Grant | 4,079 | 8.93 | 36.4K | 4,079 | D | ↗ |
| 2025-03-31 | Thackray Helen M. | Officer | F-InKind | D | Common Stock | 7,525 | 7.50 | 56.4K | 377,318 | D | ↗ |
| 2025-02-28 | MILANO VINCENT | Director | A-Award | A | Common Stock | 653 | 8.61 | 5.6K | 76,737 | D | ↗ |
| 2024-12-20 | Stonehouse Jon P | Director / Officer | G-Gift | A | Common Stock | 10,000 | 0.00 | — | 30,000 | I | ↗ |
| 2024-12-19 | Thackray Helen M. | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 260,950 | 7.39 | 1.93M | 260,950 | D | ↗ |
| 2024-12-19 | Stonehouse Jon P | Director / Officer | A-Award | A | Common Stock | 362,100 | 0.00 | — | 1,463,119 | D | ↗ |
| 2024-12-19 | Gayer Charles K | Officer | A-Award | A | Common Stock | 125,950 | 0.00 | — | 426,007 | D | ↗ |
| 2024-12-19 | Doyle Anthony | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 250,100 | 7.39 | 1.85M | 250,100 | D | ↗ |
| 2024-12-19 | Barnes Alane P | Officer | F-InKind | D | Common Stock | 2,461 | 7.39 | 18.2K | 412,729 | D | ↗ |
| 2024-12-14 | Thackray Helen M. | Officer | F-InKind | D | Common Stock | 7,150 | 7.53 | 53.8K | 264,989 | D | ↗ |
| 2024-12-14 | Stonehouse Jon P | Director / Officer | F-InKind | D | Common Stock | 27,525 | 7.53 | 207.3K | 1,101,019 | D | ↗ |
| 2024-12-14 | Gayer Charles K | Officer | F-InKind | D | Common Stock | 8,251 | 7.53 | 62.1K | 300,057 | D | ↗ |
| 2024-12-14 | Dullinger Ronald | Officer | — | — | Emp. Stock Option (Right to Buy) | 57,100 | 6.43 | 367.2K | 0 | D | ↗ |
| 2024-12-14 | Doyle Anthony | Officer | F-InKind | D | Common Stock | 7,890 | 7.53 | 59.4K | 259,628 | D | ↗ |
| 2024-12-14 | Barnes Alane P | Officer | F-InKind | D | Common Stock | 8,613 | 7.53 | 64.9K | 294,490 | D | ↗ |
| 2024-12-13 | Hutson Nancy J | Director | S-Sale | D | Common Stock | 7,000 | 7.54 | 52.8K | 86,638 | D | ↗ |
| 2024-11-29 | MILANO VINCENT | Director | A-Award | A | Common Stock | 750 | 7.50 | 5.6K | 76,084 | D | ↗ |
| 2024-08-30 | MILANO VINCENT | Director | A-Award | A | Common Stock | 647 | 8.69 | 5.6K | 75,334 | — | ↗ |
| 2024-06-24 | McKee Amy E | Director | S-Sale | D | Common Stock | 8,600 | 6.32 | 54.4K | 27,831 | — | ↗ |
| 2024-06-17 | SANDERS MACHELLE | Director | S-Sale | D | Common Stock | 4,689 | 6.00 | 28.1K | 27,742 | — | ↗ |
| 2024-06-14 | HEGGIE THERESA | Director | S-Sale | D | Common Stock | 6,698 | 6.11 | 40.9K | 52,852 | — | ↗ |
| 2024-06-12 | SANDERS MACHELLE | Director | A-Award | A | Common Stock | 6,820 | 0.00 | — | 32,431 | — | ↗ |
| 2024-06-12 | McKee Amy E | Director | A-Award | A | Common Stock | 6,820 | 0.00 | — | 36,431 | — | ↗ |
| 2024-06-12 | MILANO VINCENT | Director | A-Award | A | Automatic Stock Option Grant | 49,933 | 6.30 | 314.6K | 49,933 | — | ↗ |
| 2024-06-12 | LEVIN ALAN G | Director | A-Award | A | Automatic Stock Option Grant | 49,933 | 6.30 | 314.6K | 49,933 | — | ↗ |
| 2024-06-12 | Hutson Nancy J | Director | A-Award | A | Common Stock | 6,820 | 0.00 | — | 93,638 | — | ↗ |
| 2024-06-12 | HEGGIE THERESA | Director | A-Award | A | Automatic Stock Option Grant | 49,933 | 6.30 | 314.6K | 49,933 | — | ↗ |
| 2024-06-12 | Galson Steven K | Director | A-Award | A | Common Stock | 6,820 | 0.00 | — | 36,431 | — | ↗ |
| 2024-06-12 | ASELAGE STEVE | Director | A-Award | A | Automatic Stock Option Grant | 49,933 | 6.30 | 314.6K | 49,933 | — | ↗ |
| 2024-06-12 | ABERCROMBIE GEORGE B | Director | A-Award | A | Automatic Stock Option Grant | 49,933 | 6.30 | 314.6K | 49,933 | — | ↗ |
| 2024-05-31 | MILANO VINCENT | Director | A-Award | A | Common Stock | 870 | 6.46 | 5.6K | 67,867 | — | ↗ |
| 2024-05-31 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 870 | 6.46 | 5.6K | 52,730 | — | ↗ |
| 2024-05-30 | LEVIN ALAN G | Director | P-Purchase | A | Common Stock | 7,861 | 6.36 | 50.0K | 44,951 | — | ↗ |
| 2024-05-24 | ASELAGE STEVE | Director | P-Purchase | A | Common Stock | 2,500 | 6.40 | 16.0K | 2,500 | — | ↗ |
| 2024-05-20 | MILANO VINCENT | Director | P-Purchase | A | Common Stock | 15,000 | 6.25 | 93.8K | 66,997 | — | ↗ |
| 2024-05-20 | Hutson Nancy J | Director | P-Purchase | A | Common Stock | 5,000 | 6.38 | 31.9K | 86,818 | — | ↗ |
| 2024-05-14 | Thackray Helen M. | Officer | P-Purchase | A | Common Stock | 30,000 | 5.86 | 175.8K | 272,139 | — | ↗ |
| 2024-05-14 | Doyle Anthony | Officer | P-Purchase | A | Common Stock | 36,300 | 5.57 | 202.2K | 266,744 | — | ↗ |
| 2024-05-13 | Stonehouse Jon P | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 5.55 | 166.5K | 1,127,770 | — | ↗ |
| 2024-05-13 | Gayer Charles K | Officer | P-Purchase | A | Common Stock | 30,000 | 5.47 | 164.1K | 307,533 | — | ↗ |
| 2024-05-13 | Galson Steven K | Director | P-Purchase | A | Common Stock | 21,940 | 5.49 | 120.5K | 51,551 | — | ↗ |
| 2024-05-13 | Barnes Alane P | Officer | P-Purchase | A | Common Stock | 5,000 | 5.53 | 27.7K | 300,762 | — | ↗ |
| 2024-03-31 | Thackray Helen M. | Officer | F-InKind | D | Common Stock | 7,525 | 5.08 | 38.2K | 242,139 | — | ↗ |
| 2024-02-29 | MILANO VINCENT | Director | A-Award | A | Common Stock | 999 | 5.63 | 5.6K | 51,997 | — | ↗ |
| 2024-02-29 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 999 | 5.63 | 5.6K | 51,860 | — | ↗ |
| 2024-01-03 | Stonehouse Jon P | Director / Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 1,094,770 | — | ↗ |
| 2023-12-19 | Thackray Helen M. | Officer | F-InKind | D | Common Stock | 5,580 | 6.05 | 33.8K | 249,664 | — | ↗ |
| 2023-12-19 | Stonehouse Jon P | Director / Officer | F-InKind | D | Common Stock | 14,089 | 6.05 | 85.2K | 1,114,770 | — | ↗ |
| 2023-12-19 | Gayer Charles K | Officer | F-InKind | D | Common Stock | 2,482 | 6.05 | 15.0K | 274,533 | — | ↗ |
| 2023-12-19 | Dullinger Ronald | Officer | — | — | Emp. Stock Option (Right to Buy) | 57,100 | 10.63 | 607.0K | 0 | D | ↗ |
| 2023-12-19 | Doyle Anthony | Officer | F-InKind | D | Common Stock | 2,482 | 6.05 | 15.0K | 227,444 | — | ↗ |
| 2023-12-19 | Barnes Alane P | Officer | F-InKind | D | Common Stock | 2,482 | 6.05 | 15.0K | 293,539 | — | ↗ |
| 2023-12-14 | Thackray Helen M. | Officer | A-Award | A | Common Stock | 51,000 | 0.00 | — | 258,275 | — | ↗ |
| 2023-12-14 | Stonehouse Jon P | Director / Officer | A-Award | A | Common Stock | 127,500 | 0.00 | — | 1,142,451 | — | ↗ |
| 2023-12-14 | Gayer Charles K | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 158,500 | 6.43 | 1.02M | 158,500 | — | ↗ |
| 2023-12-14 | Doyle Anthony | Officer | A-Award | A | Common Stock | 34,000 | 0.00 | — | 235,401 | — | ↗ |
| 2023-12-14 | Barnes Alane P | Officer | A-Award | A | Common Stock | 64,000 | 0.00 | — | 300,036 | — | ↗ |
| 2023-11-30 | MILANO VINCENT | Director | A-Award | A | Common Stock | 956 | 5.88 | 5.6K | 50,998 | — | ↗ |
| 2023-11-30 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 956 | 5.88 | 5.6K | 50,861 | — | ↗ |
| 2023-08-31 | MILANO VINCENT | Director | A-Award | A | Common Stock | 791 | 7.11 | 5.6K | 50,042 | — | ↗ |
| 2023-08-31 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 791 | 7.11 | 5.6K | 49,905 | — | ↗ |
| 2023-06-15 | SANDERS MACHELLE | Director | S-Sale | D | Common Stock | 4,000 | 7.98 | 31.9K | 25,611 | — | ↗ |
| 2023-06-14 | Hutson Nancy J | Director | S-Sale | D | Common Stock | 12,866 | 8.04 | 103.4K | 81,818 | — | ↗ |
| 2023-06-13 | Stonehouse Jon P | Director / Officer | G-Gift | D | Common Stock | 25,000 | 0.00 | — | 1,014,794 | — | ↗ |
| 2023-06-13 | SANDERS MACHELLE | Director | A-Award | A | Automatic Stock Option Grant | 39,072 | 8.18 | 319.6K | 39,072 | — | ↗ |
| 2023-06-13 | McKee Amy E | Director | A-Award | A | Automatic Stock Option Grant | 39,072 | 8.18 | 319.6K | 39,072 | — | ↗ |
| 2023-06-13 | MILANO VINCENT | Director | A-Award | A | Automatic Stock Option Grant | 39,072 | 8.18 | 319.6K | 39,072 | — | ↗ |
| 2023-06-13 | LEVIN ALAN G | Director | A-Award | A | Common Stock | 16,745 | 0.00 | — | 37,090 | — | ↗ |
| 2023-06-13 | LEE KENNETH B JR | Director | A-Award | A | Automatic Stock Option Grant | 39,072 | 8.18 | 319.6K | 39,072 | — | ↗ |
| 2023-06-13 | Hutson Nancy J | Director | A-Award | A | Automatic Stock Option Grant | 39,072 | 8.18 | 319.6K | 39,072 | — | ↗ |
| 2023-06-13 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 16,745 | 0.00 | — | 49,114 | — | ↗ |
| 2023-06-13 | Galson Steven K | Director | A-Award | A | Common Stock | 16,745 | 0.00 | — | 29,611 | — | ↗ |
| 2023-06-13 | ASELAGE STEVE | Director | A-Award | A | Automatic Stock Option Grant | 39,072 | 8.18 | 319.6K | 39,072 | — | ↗ |
| 2023-06-13 | ABERCROMBIE GEORGE B | Director | A-Award | A | Common Stock | 16,745 | 0.00 | — | 29,611 | — | ↗ |
| 2023-05-31 | MILANO VINCENT | Director | A-Award | A | Common Stock | 680 | 8.27 | 5.6K | 32,506 | — | ↗ |
| 2023-05-31 | LEVIN ALAN G | Director | A-Award | A | Common Stock | 1,360 | 8.27 | 11.2K | 20,345 | — | ↗ |
| 2023-05-31 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 680 | 8.27 | 5.6K | 32,369 | — | ↗ |
| 2023-04-03 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 7,000 | 8.29 | 58.0K | 207,275 | — | ↗ |
| 2023-03-21 | Stonehouse Jon P | Director / Officer | M-Exempt | D | Emp. Stock Option (Right to Buy) | 31,055 | 3.22 | 100.0K | 305,995 | — | ↗ |
| 2023-02-28 | MILANO VINCENT | Director | A-Award | A | Common Stock | 635 | 8.85 | 5.6K | 31,826 | — | ↗ |
| 2023-02-28 | LEVIN ALAN G | Director | A-Award | A | Common Stock | 1,271 | 8.85 | 11.2K | 18,985 | — | ↗ |
| 2023-02-28 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 2,259 | 8.85 | 20.0K | 100,198 | — | ↗ |
| 2023-02-28 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 635 | 8.85 | 5.6K | 31,689 | — | ↗ |
| 2023-02-01 | Stonehouse Jon P | Director / Officer | M-Exempt | D | Emp. Stock Option (Right to Buy) | 100,000 | 5.45 | 545.0K | 0 | — | ↗ |
| 2023-01-31 | LEE KENNETH B JR | Director | M-Exempt | A | Common Stock | 15,000 | 1.71 | 25.7K | 52,118 | — | ↗ |
| 2022-12-29 | Stonehouse Jon P | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 1,008,739 | — | ↗ |
| 2022-12-19 | Thackray Helen M. | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 238,000 | 0.00 | — | 238,000 | — | ↗ |
| 2022-12-19 | Stonehouse Jon P | Officer | A-Award | A | Common Stock | 127,500 | 0.00 | — | 1,015,230 | — | ↗ |
| 2022-12-19 | Jones Michael L | Director / Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 8,500 | 0.00 | — | 8,500 | — | ↗ |
| 2022-12-19 | Gayer Charles K | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 158,500 | 0.00 | — | 158,500 | — | ↗ |
| 2022-12-19 | Doyle Anthony | Officer | A-Award | A | Common Stock | 34,000 | 0.00 | — | 197,966 | — | ↗ |
| 2022-12-19 | Barnes Alane P | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 158,500 | 0.00 | — | 158,500 | — | ↗ |
| 2022-12-15 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 3,125 | 10.89 | 34.0K | 133,275 | — | ↗ |
| 2022-12-15 | Stonehouse Jon P | Officer | S-Sale | D | Common Stock | 14,100 | 10.90 | 153.7K | 887,730 | — | ↗ |
| 2022-12-15 | Jones Michael L | Director / Officer | S-Sale | D | Common Stock | 445 | 10.90 | 4.9K | 10,753 | — | ↗ |
| 2022-12-15 | Gayer Charles K | Officer | S-Sale | D | Common Stock | 6,100 | 10.90 | 66.5K | 211,610 | — | ↗ |
| 2022-12-15 | Doyle Anthony | Officer | S-Sale | D | Common Stock | 5,700 | 10.90 | 62.1K | 163,966 | — | ↗ |
| 2022-12-15 | Barnes Alane P | Officer | S-Sale | D | Common Stock | 4,175 | 10.88 | 45.4K | 198,770 | — | ↗ |
| 2022-12-14 | Dullinger Ronald | Officer | — | — | Emp. Stock Option (Right to Buy) | 41,000 | 11.43 | 468.6K | 0 | D | ↗ |
| 2022-12-02 | Stonehouse Jon P | Officer | M-Exempt | D | Emp. Stock Option (Right to Buy) | 82,656 | 0.00 | — | 0 | — | ↗ |
| 2022-12-01 | Stonehouse Jon P | Officer | M-Exempt | A | Common Stock | 214,917 | 1.42 | 305.2K | 1,116,747 | — | ↗ |
| 2022-12-01 | Jones Michael L | Director / Officer | M-Exempt | A | Common Stock | 8,600 | 1.42 | 12.2K | 19,798 | — | ↗ |
| 2022-11-30 | MILANO VINCENT | Director | A-Award | A | Common Stock | 421 | 13.36 | 5.6K | 31,191 | — | ↗ |
| 2022-11-30 | LEVIN ALAN G | Director | A-Award | A | Common Stock | 842 | 13.36 | 11.2K | 17,714 | — | ↗ |
| 2022-11-30 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 1,497 | 13.36 | 20.0K | 97,939 | — | ↗ |
| 2022-11-30 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 421 | 13.36 | 5.6K | 31,054 | — | ↗ |
| 2022-11-14 | Babu Yarlagadda S | Officer | M-Exempt | A | Common Stock | 50,000 | 1.42 | 71.0K | 330,056 | — | ↗ |
| 2022-08-31 | MILANO VINCENT | Director | A-Award | A | Common Stock | 404 | 13.90 | 5.6K | 30,770 | — | ↗ |
| 2022-08-31 | LEVIN ALAN G | Director | A-Award | A | Common Stock | 809 | 13.90 | 11.2K | 16,872 | — | ↗ |
| 2022-08-31 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 1,438 | 13.90 | 20.0K | 96,442 | — | ↗ |
| 2022-08-31 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 404 | 13.90 | 5.6K | 30,633 | — | ↗ |
| 2022-06-07 | SANDERS MACHELLE | Director | A-Award | A | Common Stock | 12,866 | 0.00 | — | 12,866 | — | ↗ |
| 2022-06-07 | McKee Amy E | Director | A-Award | A | Automatic Stock Option Grant | 30,022 | 0.00 | — | 30,022 | — | ↗ |
| 2022-06-07 | MILANO VINCENT | Director | A-Award | A | Automatic Stock Option Grant | 30,022 | 10.79 | 323.9K | 30,022 | — | ↗ |
| 2022-06-07 | LEVIN ALAN G | Director | A-Award | A | Automatic Stock Option Grant | 30,022 | 0.00 | — | 30,022 | — | ↗ |
| 2022-06-07 | LEE KENNETH B JR | Director | A-Award | A | Common Stock | 12,866 | 0.00 | — | 37,118 | — | ↗ |
| 2022-06-07 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Automatic Stock Option Grant | 30,022 | 0.00 | — | 30,022 | — | ↗ |
| 2022-06-07 | Hutson Nancy J | Director | A-Award | A | Automatic Stock Option Grant | 30,022 | 10.79 | 323.9K | 30,022 | — | ↗ |
| 2022-06-07 | HEGGIE THERESA | Director | A-Award | A | Automatic Stock Option Grant | 30,022 | 0.00 | — | 30,022 | — | ↗ |
| 2022-06-07 | Galson Steven K | Director | A-Award | A | Common Stock | 12,866 | 0.00 | — | 12,866 | — | ↗ |
| 2022-06-07 | ASELAGE STEVE | Director | A-Award | A | Automatic Stock Option Grant | 30,022 | 10.79 | 323.9K | 30,022 | — | ↗ |
| 2022-06-07 | ABERCROMBIE GEORGE B | Director | A-Award | A | Automatic Stock Option Grant | 30,022 | 10.79 | 323.9K | 30,022 | — | ↗ |
| 2022-05-31 | LEVIN ALAN G | Director | A-Award | A | Common Stock | 1,138 | 9.31 | 10.6K | 3,197 | — | ↗ |
| 2022-05-31 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 2,078 | 9.31 | 19.3K | 82,138 | — | ↗ |
| 2022-05-31 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 1,138 | 9.31 | 10.6K | 17,363 | — | ↗ |
| 2022-05-31 | ASELAGE STEVE | Director | A-Award | A | Common Stock | 569 | 9.31 | 5.3K | 33,728 | — | ↗ |
| 2022-04-18 | ABERCROMBIE GEORGE B | Director | M-Exempt | A | Common Stock | 5,000 | 3.32 | 16.6K | 5,000 | — | ↗ |
| 2022-04-01 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 7,600 | 16.20 | 123.1K | 136,400 | — | ↗ |
| 2022-03-10 | Sheridan William P | Officer | M-Exempt | A | Common Stock | 148,302 | 3.22 | 477.5K | 199,093 | — | ↗ |
| 2022-03-07 | Babu Yarlagadda S | Officer | S-Sale | D | Common Stock | 20,000 | 17.16 | 343.2K | 230,056 | — | ↗ |
| 2022-03-01 | Jones Michael L | Director / Officer | M-Exempt | A | Common Stock | 2,300 | 4.73 | 10.9K | 13,498 | — | ↗ |
| 2022-02-28 | LEVIN ALAN G | Director | A-Award | A | Common Stock | 602 | 16.61 | 10.0K | 2,059 | — | ↗ |
| 2022-02-28 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 1,128 | 16.61 | 18.7K | 80,060 | — | ↗ |
| 2022-02-28 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 602 | 16.61 | 10.0K | 16,225 | — | ↗ |
| 2022-02-28 | ASELAGE STEVE | Director | A-Award | A | Common Stock | 301 | 16.61 | 5.0K | 33,159 | — | ↗ |
| 2022-02-15 | ABERCROMBIE GEORGE B | Director | M-Exempt | A | Common Stock | 5,000 | 3.32 | 16.6K | 5,000 | — | ↗ |
| 2022-02-08 | SANDERS MACHELLE | Director | A-Award | A | Non-Qualified Stock Option | 26,667 | 17.20 | 458.7K | 26,667 | — | ↗ |
| 2022-01-11 | Stonehouse Jon P | Director / Officer | M-Exempt | A | Common Stock | 184,000 | 4.73 | 870.3K | 1,085,602 | — | ↗ |
| 2021-12-15 | Dullinger Ronald | Officer | — | — | Emp. Stock Option (Right to Buy) | 100,000 | 8.31 | 831.0K | 0 | D | ↗ |
| 2021-12-14 | Thackray Helen M. | Officer | A-Award | A | Common Stock | 44,000 | 0.00 | — | 144,000 | — | ↗ |
| 2021-12-14 | Stonehouse Jon P | Director / Officer | A-Award | A | Common Stock | 123,000 | 0.00 | — | 901,602 | — | ↗ |
| 2021-12-14 | Sheridan William P | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 164,000 | 11.43 | 1.87M | 164,000 | — | ↗ |
| 2021-12-14 | Jones Michael L | Director / Officer | A-Award | A | Common Stock | 5,850 | 0.00 | — | 11,198 | — | ↗ |
| 2021-12-14 | Gayer Charles K | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 164,000 | 11.43 | 1.87M | 164,000 | — | ↗ |
| 2021-12-14 | Doyle Anthony | Officer | A-Award | A | Common Stock | 115,000 | 0.00 | — | 208,719 | — | ↗ |
| 2021-12-14 | Barnes Alane P | Officer | A-Award | A | Emp. Stock Option (Right to Buy) | 164,000 | 11.43 | 1.87M | 164,000 | — | ↗ |
| 2021-12-14 | Babu Yarlagadda S | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 250,056 | — | ↗ |
| 2021-12-07 | Babu Yarlagadda S | Officer | S-Sale | D | Common Stock | 30,100 | 12.20 | 367.2K | 215,056 | — | ↗ |
| 2021-11-30 | LEVIN ALAN G | Director | A-Award | A | Common Stock | 829 | 12.06 | 10.0K | 1,457 | — | ↗ |
| 2021-11-30 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 1,554 | 12.06 | 18.7K | 78,932 | — | ↗ |
| 2021-11-30 | HEGGIE THERESA | Director | A-Award | A | Common Stock | 829 | 12.06 | 10.0K | 15,623 | — | ↗ |
Executive team
Top executives
EBIT / Employee
597.0K
Shares Outstanding
209.89M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jon P. Stonehouse Former President and Chief Executive Officer | 728.5K | — | — | 11.13M | 1.05M | 37.5K | 12.95M | 85.96% | ↗ |
| 2 | 2025 | Charles K. Gayer President and Chief Executive Officer; Former Chief Commercial Officer | 609.4K | — | 3.36M | 4.89M | 749.1K | 17.5K | 9.63M | 85.71% | ↗ |
| 3 | 2025 | Babar Ghias Chief Financial Officer | 271.5K | 160.0K | 2.12M | 3.68M | 506.4K | 10.5K | 6.75M | 85.95% | ↗ |
| 4 | 2025 | Alane P. Barnes Chief Legal Officer and Corporate Secretary | 542.5K | — | 867.7K | 3.63M | 553.4K | 17.5K | 5.62M | 80.17% | ↗ |
| 5 | 2025 | Helen M. Thackray, M.D. Former Chief R&D Officer | 426.0K | — | 1.17M | 1.26M | 756.1K | 733.3K | 4.34M | 55.86% | ↗ |
| 6 | 2025 | Anthony J. Doyle Former Chief Financial Officer and Treasurer | 151.9K | — | 708.7K | 1.17M | — | 114.7K | 2.14M | 87.55% | ↗ |
| 7 | 2024 | Jon P. Stonehouse Former President and Chief Executive Officer | 705.5K | — | 2.68M | 4.00M | 899.6K | 34.1K | 8.32M | 80.29% | ↗ |
| 8 | 2024 | Jon P. Stonehouse President, Chief Executive Officer, Interim Chief Financial Officer, and Director | 705.5K | — | 2.68M | 4.00M | 899.6K | 34.1K | 8.32M | 80.29% | ↗ |
| 9 | 2024 | Helen M. Thackray, M.D. Chief R&D Officer | 599.4K | — | 930.8K | 1.39M | 629.4K | 17.3K | 3.57M | 65.08% | ↗ |
| 10 | 2024 | Helen M. Thackray, M.D. Former Chief R&D Officer | 599.4K | — | 930.8K | 1.39M | 629.4K | 17.3K | 3.57M | 65.08% | ↗ |
| 11 | 2024 | Charles K. Gayer Chief Commercial Officer | 544.8K | — | 930.8K | 1.39M | 490.3K | 17.3K | 3.38M | 68.82% | ↗ |
| 12 | 2024 | Charles K. Gayer President and Chief Executive Officer; Former Chief Commercial Officer | 544.8K | — | 930.8K | 1.39M | 490.3K | 17.3K | 3.38M | 68.82% | ↗ |
| 13 | 2024 | Anthony J. Doyle Former Chief Financial Officer and Treasurer | 549.4K | — | 892.0K | 1.33M | 494.5K | 17.3K | 3.29M | 67.72% | ↗ |
| 14 | 2024 | Alane P. Barnes Chief Legal Officer and Corporate Secretary | 525.4K | — | 892.0K | 1.33M | 472.9K | 17.3K | 3.24M | 68.67% | ↗ |
| 15 | 2023 | Jon P. Stonehouse President, Chief Executive Officer, Interim Chief Financial Officer, and Director | 665.6K | — | 819.8K | 2.72M | 537.5K | 30.3K | 4.78M | 74.19% | ↗ |
| 16 | 2023 | Jon P. Stonehouse Former President and Chief Executive Officer | 665.6K | — | 819.8K | 2.72M | 537.5K | 30.3K | 4.78M | 74.19% | ↗ |
| 17 | 2023 | Jon P. Stonehouse President, Chief Executive Officer and Director | 665.6K | — | 819.8K | 2.72M | 537.5K | 30.3K | 4.78M | 74.19% | ↗ |
| 18 | 2023 | Helen M. Thackray, M.D. Former Chief R&D Officer | 576.4K | — | 327.9K | 1.09M | 383.3K | 16.5K | 2.39M | 59.22% | ↗ |
| 19 | 2023 | Helen M. Thackray, M.D. Chief R&D Officer | 576.4K | — | 327.9K | 1.09M | 383.3K | 16.5K | 2.39M | 59.22% | ↗ |
| 20 | 2023 | Alane P. Barnes Chief Legal Officer and Corporate Secretary | 495.7K | — | 411.5K | 725.8K | 282.5K | 16.5K | 1.93M | 58.87% | ↗ |
| 21 | 2023 | Anthony J. Doyle Chief Financial Officer and Treasurer | 528.3K | — | 218.6K | 725.8K | 301.1K | 16.5K | 1.79M | 52.75% | ↗ |
| 22 | 2023 | Anthony J. Doyle Former Chief Financial Officer and Treasurer | 528.3K | — | 218.6K | 725.8K | 301.1K | 16.5K | 1.79M | 52.75% | ↗ |
| 23 | 2023 | Charles K. Gayer President and Chief Executive Officer; Former Chief Commercial Officer | 495.3K | — | 218.6K | 725.8K | 282.3K | 16.5K | 1.74M | 54.32% | ↗ |
| 24 | 2023 | Charles K. Gayer Chief Commercial Officer | 495.3K | — | 218.6K | 725.8K | 282.3K | 16.5K | 1.74M | 54.32% | ↗ |
| 25 | 2022 | Jon P. Stonehouse President, Chief Executive Officer and Director | 640.0K | — | 1.36M | 4.48M | 480.0K | 25.4K | 6.98M | 83.60% | ↗ |
| 26 | 2022 | Jon P. Stonehouse President, Chief Executive Officer, Interim Chief Financial Officer, and Director | 640.0K | — | 1.36M | 4.48M | 480.0K | 25.4K | 6.98M | 83.60% | ↗ |
| 27 | 2022 | Helen M. Thackray, M.D. Chief R&D Officer | 554.2K | — | 861.0K | 1.79M | 277.1K | 12.7K | 3.50M | 75.87% | ↗ |
| 28 | 2022 | William P. Sheridan, MBBS Chief Development Officer | 549.2K | — | 680.3K | 1.19M | 219.7K | 15.3K | 2.66M | 70.51% | ↗ |
| 29 | 2022 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 483.0K | — | 680.3K | 1.19M | 193.2K | 15.3K | 2.57M | 73.05% | ↗ |
| 30 | 2022 | Anthony J. Doyle Former Chief Financial Officer and Treasurer | 508.0K | — | 361.4K | 1.19M | 203.2K | 15.3K | 2.28M | 68.17% | ↗ |
| 31 | 2022 | Anthony J. Doyle Chief Financial Officer and Treasurer | 508.0K | — | 361.4K | 1.19M | 203.2K | 15.3K | 2.28M | 68.17% | ↗ |
| 32 | 2022 | Alane P. Barnes Chief Legal Officer and Corporate Secretary | 457.2K | — | 361.4K | 1.19M | 182.9K | 15.3K | 2.21M | 70.36% | ↗ |
| 33 | 2022 | Charles K. Gayer Chief Commercial Officer | 448.7K | — | 361.4K | 1.19M | 179.5K | 15.3K | 2.20M | 70.74% | ↗ |
| 34 | 2021 | Megan T. Sniecinski Former Chief Business Officer | 286.2K | — | — | 6.95M | — | 690.9K | 7.93M | 87.68% | ↗ |
| 35 | 2021 | Jon P. Stonehouse President, Chief Executive Officer and Director | 583.5K | 43.8K | 1.41M | 4.51M | 492.3K | 24.7K | 7.06M | 83.80% | ↗ |
| 36 | 2021 | Helen M. Thackray, M.D. Chief R&D Officer | 425.1K | 236.5K | 1.52M | 4.40M | 298.1K | 6.6K | 6.88M | 85.96% | ↗ |
| 37 | 2021 | Anthony J. Doyle Chief Financial Officer and Treasurer | 490.8K | 19.6K | 857.3K | 1.29M | 220.9K | 14.5K | 2.89M | 74.20% | ↗ |
| 38 | 2021 | Anthony J. Doyle Chief Financial Officer | 490.8K | 19.6K | 857.3K | 1.29M | 220.9K | 14.5K | 2.89M | 74.20% | ↗ |
| 39 | 2021 | William P. Sheridan, MBBS Chief Medical Officer | 530.6K | 21.2K | 400.1K | 1.29M | 238.8K | 52.8K | 2.53M | 66.68% | ↗ |
| 40 | 2021 | William P. Sheridan, MBBS Chief Development Officer | 530.6K | 21.2K | 400.1K | 1.29M | 238.8K | 52.8K | 2.53M | 66.68% | ↗ |
| 41 | 2021 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 458.9K | 18.4K | 400.1K | 1.29M | 206.5K | 14.5K | 2.39M | 70.73% | ↗ |
| 42 | 2020 | Jon P. Stonehouse President, Chief Executive Officer and Director | 566.5K | — | — | 4.92M | 531.1K | 21.3K | 6.03M | 81.46% | ↗ |
| 43 | 2020 | Anthony J. Doyle Chief Financial Officer | 345.5K | 50.0K | — | 3.47M | 240.0K | 14.3K | 4.12M | 84.22% | ↗ |
| 44 | 2020 | Anthony J. Doyle Chief Financial Officer and Treasurer | 345.5K | 50.0K | — | 3.47M | 240.0K | 14.3K | 4.12M | 84.22% | ↗ |
| 45 | 2020 | William P. Sheridan, MBBS Chief Development Officer | 515.1K | — | — | 1.89M | 257.6K | 14.3K | 2.68M | 70.63% | ↗ |
| 46 | 2020 | William P. Sheridan, MBBS Chief Medical Officer | 515.1K | — | — | 1.89M | 257.6K | 14.3K | 2.68M | 70.63% | ↗ |
| 47 | 2020 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 445.6K | — | — | 1.58M | 222.8K | 14.3K | 2.26M | 69.86% | ↗ |
| 48 | 2020 | Megan T. Sniecinski Former Chief Business Officer | 456.8K | — | — | 1.27M | 228.4K | 55.8K | 2.01M | 63.18% | ↗ |
| 49 | 2020 | Megan T. Sniecinski Chief Business Officer | 456.8K | — | — | 1.27M | 228.4K | 55.8K | 2.01M | 63.18% | ↗ |
| 50 | 2020 | Thomas R. Staab II Former Senior Vice President and Chief Financial Officer | 77.1K | — | — | — | — | 615.7K | 692.8K | 0.00% | ↗ |
| 51 | 2019 | Jon P. Stonehouse President, Chief Executive Officer and Director | 550.0K | — | — | 1.37M | 350.6K | 14.9K | 2.28M | 59.92% | ↗ |
| 52 | 2019 | Megan T. Sniecinski Senior Vice President and Chief Business Officer | 225.0K | — | — | 1.77M | 153.0K | 25.6K | 2.18M | 81.46% | ↗ |
| 53 | 2019 | Megan T. Sniecinski Chief Business Officer | 225.0K | — | — | 1.77M | 153.0K | 25.6K | 2.18M | 81.46% | ↗ |
| 54 | 2019 | Megan T. Sniecinski Former Chief Business Officer | 225.0K | — | — | 1.77M | 153.0K | 25.6K | 2.18M | 81.46% | ↗ |
| 55 | 2019 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 432.6K | — | — | 489.6K | 147.1K | 14.0K | 1.08M | 45.20% | ↗ |
| 56 | 2019 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 432.6K | — | — | 489.6K | 147.1K | 14.0K | 1.08M | 45.20% | ↗ |
| 57 | 2019 | William P. Sheridan Senior Vice President and Chief Medical Officer | 500.1K | — | — | 383.0K | 170.0K | 14.0K | 1.07M | 35.89% | ↗ |
| 58 | 2019 | William P. Sheridan, MBBS Chief Medical Officer | 500.1K | — | — | 383.0K | 170.0K | 14.0K | 1.07M | 35.89% | ↗ |
| 59 | 2019 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 462.7K | — | — | 276.4K | 157.3K | 14.0K | 910.4K | 30.36% | ↗ |
| 60 | 2019 | Thomas R. Staab II Former Senior Vice President and Chief Financial Officer | 462.7K | — | — | 276.4K | 157.3K | 14.0K | 910.4K | 30.36% | ↗ |
| 61 | 2018 | Jon P. Stonehouse President, Chief Executive Officer and Director | 550.0K | — | — | 3.28M | 325.2K | 14.7K | 4.17M | 78.65% | ↗ |
| 62 | 2018 | William P. Sheridan, MBBS Chief Medical Officer | 485.6K | — | — | 1.63M | 208.8K | 28.1K | 2.35M | 69.25% | ↗ |
| 63 | 2018 | William P. Sheridan Senior Vice President and Chief Medical Officer | 485.6K | — | — | 1.63M | 208.8K | 28.1K | 2.35M | 69.25% | ↗ |
| 64 | 2018 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 449.2K | — | — | 1.14M | 193.2K | 13.8K | 1.80M | 63.49% | ↗ |
| 65 | 2018 | Thomas R. Staab II Former Senior Vice President and Chief Financial Officer | 449.2K | — | — | 1.14M | 193.2K | 13.8K | 1.80M | 63.49% | ↗ |
| 66 | 2018 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 420.0K | — | — | 1.14M | 180.6K | 13.8K | 1.76M | 65.00% | ↗ |
| 67 | 2018 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 420.0K | — | — | 1.14M | 180.6K | 13.8K | 1.76M | 65.00% | ↗ |
| 68 | 2018 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 382.5K | — | — | 922.6K | 164.5K | 59.1K | 1.53M | 60.36% | ↗ |
| 69 | 2017 | Jon P. Stonehouse President, Chief Executive Officer and Director | 532.8K | 243.0K | — | 2.91M | 220.9K | 14.4K | 3.92M | 74.21% | ↗ |
| 70 | 2017 | William P. Sheridan Senior Vice President and Chief Medical Officer | 469.1K | 155.6K | — | 1.00M | 141.4K | 41.1K | 1.81M | 55.36% | ↗ |
| 71 | 2017 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 434.0K | 144.0K | — | 1.00M | 130.8K | 13.5K | 1.72M | 58.09% | ↗ |
| 72 | 2017 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 382.5K | 126.9K | — | 1.00M | 115.3K | 13.5K | 1.64M | 61.07% | ↗ |
| 73 | 2017 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 369.5K | 122.6K | — | 838.5K | 111.4K | 45.1K | 1.49M | 56.39% | ↗ |
| 74 | 2016 | Jon P. Stonehouse President, Chief Executive Officer and Director | 519.8K | — | — | 736.5K | — | 14.2K | 1.27M | 57.97% | ↗ |
| 75 | 2016 | William P. Sheridan Senior Vice President and Chief Medical Officer | 457.7K | — | — | 324.0K | — | 36.4K | 818.1K | 39.61% | ↗ |
| 76 | 2016 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 423.4K | — | — | 282.8K | — | 13.3K | 719.5K | 39.31% | ↗ |
| 77 | 2016 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 360.5K | — | — | 282.8K | — | 29.6K | 672.9K | 42.02% | ↗ |
| 78 | 2016 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 373.2K | — | — | 282.8K | — | 13.3K | 669.2K | 42.26% | ↗ |
| 79 | 2015 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 327.6K | — | 113.3K | 2.69M | — | 61.9K | 3.19M | 87.80% | ↗ |
| 80 | 2015 | Lynne M. Powell Senior Vice President, Chief Commercial Officer | 327.6K | — | 113.3K | 2.69M | — | 61.9K | 3.19M | 87.80% | ↗ |
| 81 | 2015 | Jon P. Stonehouse President, Chief Executive Officer and Director | 504.7K | — | 345.3K | 2.28M | — | 14.2K | 3.15M | 83.52% | ↗ |
| 82 | 2015 | William P. Sheridan Senior Vice President and Chief Medical Officer | 444.4K | — | 132.6K | 941.1K | — | 50.6K | 1.57M | 68.45% | ↗ |
| 83 | 2015 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 411.1K | — | 108.2K | 796.4K | — | 13.3K | 1.33M | 68.07% | ↗ |
| 84 | 2015 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 362.3K | — | 108.2K | 796.4K | — | 13.3K | 1.28M | 70.67% | ↗ |
| 85 | 2014 | Jon P. Stonehouse President, Chief Executive Officer and Director | 506.2K | 127.5K | 1.38M | 640.6K | 232.7K | 13.9K | 2.90M | 69.68% | ↗ |
| 86 | 2014 | Jon P. Stonehouse President, Chief Executive Officer and Director | 506.2K | 127.5K | 1.38M | 640.6K | 232.7K | 13.9K | 2.90M | 69.68% | ↗ |
| 87 | 2014 | William P. Sheridan Senior Vice President and Chief Medical Officer | 436.4K | 67.4K | 583.2K | 1.16M | 123.0K | 25.4K | 2.39M | 72.72% | ↗ |
| 88 | 2014 | William P. Sheridan Senior Vice President and Chief Medical Officer | 436.4K | 67.4K | 583.2K | 1.16M | 123.0K | 25.4K | 2.39M | 72.72% | ↗ |
| 89 | 2014 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 399.1K | 62.3K | 583.2K | 974.4K | 113.7K | 13.0K | 2.15M | 72.59% | ↗ |
| 90 | 2014 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 399.1K | 62.3K | 583.2K | 974.4K | 113.7K | 13.0K | 2.15M | 72.59% | ↗ |
| 91 | 2014 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 405.9K | 54.9K | 583.2K | 974.4K | 100.2K | 13.0K | 2.13M | 73.07% | ↗ |
| 92 | 2014 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 405.9K | 54.9K | 583.2K | 974.4K | 100.2K | 13.0K | 2.13M | 73.07% | ↗ |
| 93 | 2014 | Alane P. Barnes Vice President, General Counsel and Corporate Secretary | 279.6K | 46.7K | 291.6K | 624.7K | 75.5K | 13.0K | 1.33M | 68.84% | ↗ |
| 94 | 2013 | Jon P. Stonehouse President, Chief Executive Officer and Director | 475.7K | — | 88.9K | 1.23M | 166.5K | 13.7K | 1.98M | 66.80% | ↗ |
| 95 | 2013 | Jon P. Stonehouse President, Chief Executive Officer and Director | 475.7K | — | 88.9K | 1.23M | 166.5K | 13.7K | 1.98M | 66.80% | ↗ |
| 96 | 2013 | William P. Sheridan Senior Vice President and Chief Medical Officer | 418.9K | — | 24.1K | 674.0K | 88.0K | 21.4K | 1.23M | 56.93% | ↗ |
| 97 | 2013 | William P. Sheridan Senior Vice President and Chief Medical Officer | 418.9K | — | 24.1K | 674.0K | 88.0K | 21.4K | 1.23M | 56.93% | ↗ |
| 98 | 2013 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 387.5K | — | 24.1K | 674.0K | 81.4K | 12.8K | 1.18M | 59.18% | ↗ |
| 99 | 2013 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 387.5K | — | 24.1K | 674.0K | 81.4K | 12.8K | 1.18M | 59.18% | ↗ |
| 100 | 2013 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 341.5K | — | 24.1K | 674.0K | 71.7K | 12.8K | 1.12M | 62.11% | ↗ |
| 101 | 2013 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 341.5K | — | 24.1K | 674.0K | 71.7K | 12.8K | 1.12M | 62.11% | ↗ |
| 102 | 2013 | Alane P. Barnes Vice President, General Counsel and Corporate Secretary | 231.7K | — | 24.1K | 674.0K | 48.7K | 11.6K | 990.1K | 70.51% | ↗ |
| 103 | 2013 | Alane P. Barnes Vice President, General Counsel and Corporate Secretary | 231.7K | — | 24.1K | 674.0K | 48.7K | 11.6K | 990.1K | 70.51% | ↗ |
| 104 | 2012 | Jon P. Stonehouse President, Chief Executive Officer and Director | 461.9K | — | 157.3K | 612.1K | — | 13.4K | 1.24M | 61.81% | ↗ |
| 105 | 2012 | William P. Sheridan Senior Vice President and Chief Medical Officer | 405.3K | — | 40.2K | 559.5K | — | 12.5K | 1.02M | 58.94% | ↗ |
| 106 | 2012 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 330.5K | — | 53.0K | 206.2K | — | 12.5K | 602.2K | 43.05% | ↗ |
| 107 | 2012 | Yarlagadda S. Babu, Ph.D. Vice President, Drug Discovery | 330.5K | — | 53.0K | 206.2K | — | 12.5K | 602.2K | 43.05% | ↗ |
| 108 | 2012 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 375.2K | — | 26.5K | 103.1K | — | 12.5K | 517.3K | 25.06% | ↗ |
| 109 | 2012 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 269.7K | — | 40.2K | 166.3K | — | 6.4K | 482.7K | 42.79% | ↗ |
| 110 | 2011 | Jon P. Stonehouse President, Chief Executive Officer and Director | 459.6K | — | 118.3K | 465.4K | 219.4K | 13.7K | 1.28M | 45.73% | ↗ |
| 111 | 2011 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 185.0K | — | 94.5K | 500.0K | 62.7K | — | 842.2K | 70.59% | ↗ |
| 112 | 2011 | William P. Sheridan Senior Vice President and Chief Medical Officer | 396.7K | — | 41.5K | 152.4K | 119.6K | 12.3K | 722.4K | 26.83% | ↗ |
| 113 | 2011 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 323.5K | — | 37.4K | 138.5K | 110.0K | 12.3K | 621.6K | 28.29% | ↗ |
| 114 | 2011 | Yarlagadda S. Babu, Ph.D. Vice President, Drug Discovery | 323.5K | — | 37.4K | 138.5K | 110.0K | 12.3K | 621.6K | 28.29% | ↗ |
| 115 | 2011 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 269.4K | — | 24.9K | 110.8K | 81.1K | 12.3K | 498.5K | 27.22% | ↗ |
| 116 | 2011 | Stuart Grant Former Senior Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 117 | 2011 | Thomas R. Staab II | — | — | — | — | — | — | — | — | ↗ |
| 118 | 2010 | Jon P. Stonehouse President, Chief Executive Officer and Director | 448.4K | — | — | 589.0K | 161.4K | 12.3K | 1.21M | 48.63% | ↗ |
| 119 | 2010 | William P. Sheridan Senior Vice President and Chief Medical Officer | 387.1K | — | — | 262.1K | 83.6K | 12.3K | 745.1K | 35.18% | ↗ |
| 120 | 2010 | Stuart Grant Senior Vice President and Chief Financial Officer | 407.5K | — | — | — | 97.0K | — | 688.8K | 0.00% | ↗ |
| 121 | 2010 | Peter L. McCullough Vice President, Operations | 260.0K | 40.0K | — | — | 57.3K | 32.3K | 664.6K | 0.00% | ↗ |
| 122 | 2010 | Yarlagadda S. Babu, Ph.D. Vice President, Drug Discovery | 315.6K | — | — | 225.3K | 68.2K | 12.3K | 621.2K | 36.26% | ↗ |
| 123 | 2010 | Yarlagadda S. Babu, Ph.D Vice President, Drug Discovery | 315.6K | — | — | — | 68.2K | 12.3K | 621.2K | 0.00% | ↗ |
| 124 | 2010 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 265.0K | — | — | 225.3K | 43.7K | 12.3K | 546.3K | 41.24% | ↗ |
| 125 | 2010 | Stuart Grant Former Senior Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 126 | 2009 | Stuart Grant Senior Vice President and Chief Financial Officer | 404.0K | 309.0K | — | — | 122.3K | — | 947.7K | 0.00% | ↗ |
| 127 | 2009 | Yarlagadda S. Babu, Ph.D Vice President, Drug Discovery | 313.5K | 242.7K | — | — | 75.7K | 12.3K | 734.3K | 0.00% | ↗ |
| 128 | 2009 | Jon P. Stonehouse, President, Chief Executive Officer and Director | — | — | — | — | — | — | — | — | ↗ |
| 129 | 2009 | Jon P. Stonehouse President, Chief Executive Officer and Director | — | — | — | — | — | — | — | — | ↗ |
| 130 | 2009 | William P. Sheridan Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 131 | 2009 | Stuart Grant Former Senior Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 132 | 2009 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | — | — | — | — | — | — | — | — | ↗ |
| 133 | 2009 | William P. Sheridan, Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 134 | 2009 | Stuart Grant, Senior Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 135 | 2009 | David S. McCullough, Vice President, Strategic Planning and Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 136 | 2009 | Yarlagadda S. Babu, Ph.D, Vice President, Drug Discovery | — | — | — | — | — | — | — | — | ↗ |
| 137 | 2008 | Stuart Grant Senior Vice President and Chief Financial Officer | 384.4K | — | 77.5K | — | 115.9K | 13.1K | 747.6K | 10.37% | ↗ |
| 138 | 2008 | Jon P. Stonehouse President, Chief Executive Officer and Director | 420.8K | — | — | — | 180.7K | 11.3K | 739.8K | 0.00% | ↗ |
| 139 | 2008 | William P. Sheridan Senior Vice President and Chief Medical Officer | 187.5K | — | — | — | 52.5K | 31.5K | 605.5K | 0.00% | ↗ |
| 140 | 2008 | Yarlagadda S. Babu, Ph.D Vice President, Drug Discovery | 300.1K | — | 60.9K | — | 85.0K | 11.3K | 519.9K | 11.71% | ↗ |
| 141 | 2008 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 222.9K | — | 45.1K | — | 58.4K | 11.3K | 373.7K | 12.06% | ↗ |
| 142 | 2008 | Yarlagadda S. Babu, Ph.D, Vice President, Drug Discovery | — | — | — | — | — | — | — | — | ↗ |
| 143 | 2008 | J. Claude Bennett, M.D., Former Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 144 | 2008 | Jon P. Stonehouse, President, Chief Executive Officer and Director | — | — | — | — | — | — | — | — | ↗ |
| 145 | 2008 | David S. McCullough, Vice President, Strategic Planning and Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 146 | 2008 | David S. McCullough, Vice President, Strategic Planning and | — | — | — | — | — | — | — | — | ↗ |
| 147 | 2008 | William P. Sheridan, Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 148 | 2008 | Stuart Grant, Senior Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 149 | 2007 | W. James Alexander, M.D., MPH, Senior Vice President and Chief Medical Officer | 335.0K | 65.0K | — | — | — | 11.3K | 1.09M | 0.00% | ↗ |
| 150 | 2007 | J. Claude Bennett, M.D., Chief Operating Officer | 360.9K | 25.0K | — | — | 36.1K | 11.3K | 633.9K | 0.00% | ↗ |
| 151 | 2007 | Charles E. Bugg, Ph.D., Former Chief Executive Officer | 171.0K | — | — | — | — | 68.6K | 494.4K | 0.00% | ↗ |
| 152 | 2007 | Randall B. Riggs, Senior Vice President Business Development | 250.8K | 25.0K | — | — | — | 11.3K | 460.7K | 0.00% | ↗ |
| 153 | 2007 | Michael A. Darwin, Vice President Finance Treasurer (Former Chief Financial Officer) | 235.5K | 25.0K | — | — | 21.7K | 11.3K | 424.3K | 0.00% | ↗ |
| 154 | 2007 | William P. Sheridan, Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 155 | 2007 | David S. McCullough, Vice President, Strategic Planning and | — | — | — | — | — | — | — | — | ↗ |
| 156 | 2007 | David S. McCullough, Vice President, Strategic Planning and Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 157 | 2007 | Yarlagadda S. Babu, Ph.D, Vice President, Drug Discovery | — | — | — | — | — | — | — | — | ↗ |
| 158 | 2007 | Jon P. Stonehouse, President, Chief Executive Officer and Director | — | — | — | — | — | — | — | — | ↗ |
| 159 | 2007 | Stuart Grant, Senior Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 160 | 2007 | J. Claude Bennett, M.D., Former Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 161 | 2006 | Charles E. Bugg, Ph.D., Chairman and Chief Executive Officer | 453.4K | — | — | — | — | 11.3K | 702.5K | 0.00% | ↗ |
| 162 | 2006 | Charles E. Bugg, Ph.D., Former Chief Executive Officer | 453.4K | — | — | — | — | 11.0K | 702.1K | 0.00% | ↗ |
| 163 | 2006 | W. James Alexander, M.D., MPH, Senior Vice President and Chief Medical Officer | 172.3K | 90.0K | — | — | — | 4.3K | 654.6K | 0.00% | ↗ |
| 164 | 2006 | W. James Alexander, M.D., MPH, Senior Vice President and Chief Medical Officer | 172.3K | 90.0K | — | — | — | 4.0K | 654.4K | 0.00% | ↗ |
| 165 | 2006 | Randall B. Riggs, Senior Vice President Business Development | 290.0K | 60.0K | — | — | — | 11.4K | 619.7K | 0.00% | ↗ |
| 166 | 2006 | Randall B. Riggs, Senior Vice President Business Development | 290.0K | 60.0K | — | — | — | 11.0K | 619.2K | 0.00% | ↗ |
| 167 | 2006 | J. Claude Bennett, M.D., President and Chief Operating Officer | 347.0K | — | — | — | — | 11.2K | 531.0K | 0.00% | ↗ |
| 168 | 2006 | J. Claude Bennett, M.D., Chief Operating Officer | 347.0K | — | — | — | — | 11.0K | 530.8K | 0.00% | ↗ |
| 169 | 2006 | Michael A. Darwin , Chief Financial Officer, Secretary Treasurer | 224.2K | — | — | — | — | 11.4K | 352.1K | 0.00% | ↗ |
| 170 | 2006 | Michael A. Darwin, Vice President Finance Treasurer (Former Chief Financial Officer) | 224.2K | — | — | — | — | 11.0K | 351.7K | 0.00% | ↗ |
| 171 | 2006 | David S. McCullough, Vice President, Strategic Planning and Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 172 | 2006 | Stuart Grant, Senior Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 173 | 2006 | David S. McCullough, Vice President, Strategic Planning and | — | — | — | — | — | — | — | — | ↗ |
| 174 | 2006 | J. Claude Bennett, M.D., Former Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 175 | 2006 | Jon P. Stonehouse, President, Chief Executive Officer and Director | — | — | — | — | — | — | — | — | ↗ |
| 176 | 2005 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 425.0K | 55.4K | — | 53.7K | — | 119.3K | 599.7K | 8.95% | ↗ |
| 177 | 2005 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 325.0K | 42.4K | — | 41.1K | — | 12.4K | 379.7K | 10.81% | ↗ |
| 178 | 2005 | Randall B. Riggs, Senior Vice President Business Development | 212.5K | 75.0K | — | 80.0K | — | 10.7K | 298.2K | 26.83% | ↗ |
| 179 | 2005 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 202.5K | 27.4K | — | 33.5K | — | 10.6K | 240.5K | 13.94% | ↗ |
| 180 | 2005 | Jonathan M. P. Nugent | 117.6K | 23.5K | — | 35.0K | — | 27.2K | 168.2K | 20.81% | ↗ |
| 181 | 2004 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 400.0K | — | — | 52.6K | — | 426.3K | 826.3K | 6.37% | ↗ |
| 182 | 2004 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 304.5K | — | — | 40.1K | — | 11.8K | 316.3K | 12.66% | ↗ |
| 183 | 2004 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 169.0K | — | — | 20.7K | — | 49.3K | 218.2K | 9.49% | ↗ |
| 184 | 2003 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 300.0K | 484.5K | — | 38.5K | — | 11.6K | 796.1K | 4.83% | ↗ |
| 185 | 2003 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 228.4K | — | — | 29.3K | — | 12.8K | 241.2K | 12.14% | ↗ |
| 186 | 2003 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 142.7K | — | — | 14.7K | — | 7.0K | 149.7K | 9.85% | ↗ |
| 187 | 2002 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 274.5K | 20.00 | — | 23.2K | — | 211.2K | 485.7K | 4.77% | ↗ |
| 188 | 2002 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | — | — | — | 14.2K | — | — | — | — | ↗ |
| 189 | 2002 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | — | — | — | 30.4K | — | — | — | — | ↗ |
| 190 | 2002 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | — | — | — | 23.2K | — | — | — | — | ↗ |
| 191 | 2001 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 381.6K | — | — | — | — | 8.5K | 390.1K | 0.00% | ↗ |
| 192 | 2001 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 291.7K | 15.0K | — | — | — | 8.5K | 315.2K | 0.00% | ↗ |
| 193 | 2001 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 79.5K | — | — | — | — | 876.00 | 80.4K | 0.00% | ↗ |
| 194 | 2000 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 355.5K | 60.0K | — | 55.0K | — | 8.3K | 423.7K | 12.98% | ↗ |
| 195 | 2000 | J. Claude Bennett, M.D. President, Chief Operating Officer and | 264.5K | — | — | 37.3K | — | 8.3K | 272.7K | 13.68% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Charles K. Gayer | CEO, President & Director | 1M | male |
| Alane Barnes | Senior Vice President, Chief Legal Officer & Corporate Secretary | 1M | female |
| Babar Ghias | Chief Financial Officer & Head of Corporate Development | 948.4K | male |
| William Sheridan MBBS | Chief Development Officer | 784.1K | — |
| Yarlagadda S. Babu | Chief Discovery Officer | 691.5K | — |
| Nick Wilder | Manager of Investor Relations | — | — |
| Philip George | Chief Strategy Officer | — | male |
| Stephanie Angelini | Chief People Officer & Chief Communications Officer | — | female |
| John Ruesch | Chief Technical Operations Officer | — | male |
| Jinky Ang Rosselli | Chief Data Innovation Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BCRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
